FORUM REVIEW ARTICLE

Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

Martin Štěrba,¹ Olga Popelová,¹ Anna Vávrová,² Eduard Jirkovský,¹ Petra Kovaříková,³ Vladimír Geršl,¹ and Tomáš Šimůnek²

Abstract

Significance: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of cardiotoxicity. The most feared are the chronic forms of cardiotoxicity, characterized by irreversible cardiac damage and congestive heart failure. Although the pathogenesis of anthracycline cardiotoxicity seems to be complex, the pivotal role has been traditionally attributed to the iron-mediated formation of reactive oxygen species (ROS). In clinics, the bisdioxopiperazine agent dexrazoxane (ICRF-187) reduces the risk of anthracycline cardiotoxicity without a significant effect on response to chemotherapy. The prevailing concept describes dexrazoxane as a prodrug undergoing bioactivation to an iron-chelating agent ADR-925, which may inhibit anthracycline-induced ROS formation and oxidative damage to cardiomyocytes. **Recent Advances:** A considerable body of evidence points to mitochondria as the key targets for anthracycline cardiotoxicity, and therefore it could be also crucial for effective cardioprotection. Numerous antioxidants and several iron chelators have been tested *in vitro* and *in vivo* with variable outcomes. None of these compounds have matched or even surpassed the effectiveness of dexrazoxane in chronic anthracycline cardiotoxicity settings, despite being stronger chelators and/or antioxidants. **Critical Issues:** The interpretation of many findings is complicated by the heterogeneity of experimental models and frequent employment of acute high-dose treatments with limited translatability to clinical practice. **Future Directions:** Dexrazoxane may be the key to the enigma of anthracycline cardiotoxicity, and therefore it warrants further investigation, including the search for alternative/complementary modes of cardioprotective action beyond simple iron chelation. *Antioxid. Redox Signal.* 18, 899–929.

The Anthracyclines—History, Chemical Structure, and Pharmacology

FOLLOWING ITS ISOLATION from *Streptomyces peucetius* in 1962, daunorubicin (DAU, also known as daunomycin or rubidomycin) was the first anthracycline (ANT) antibiotic with impressive clinical activity in the treatment of acute pediatric leukemias (261). Further research in the 1960s led to the isolation of doxorubicin (DOX, also known as adriamycin) from *S. peucetius* var. *caesi* (7). DOX has been shown to possess an extremely broad range of therapeutic activities against both hematological and solid tumors, including breast, ovarian and gastric carcinoma, soft-tissue and bone

sarcoma, non-Hodgkin's and Hodgkin's lymphoma, and multiple myeloma (7). Later on, several newer ANT's have been developed, including epirubicin (EPI), with particular activity in breast, stomach, and urinary tract carcinoma (23). Furthermore, idarubicin was developed as a DAU analog with improved efficiency against acute myelogenous leukemia (24). Valrubicin, a semisynthetic analog of DOX, is unsuitable for systemic use (280) due to its toxicity, but can be administered directly into the bladder to treat bladder cancer (80). In addition, mitoxantrone, although not an ANT, shares many features with them (including cardiotoxicity) and is used for the treatment of breast or prostate cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma (75).

¹Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic.

²Department of Biochemical Sciences and ³Department of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic.

The introduction of ANTs into clinical practice has been one of the major successes of modern oncology. This is particularly evident in pediatric oncology, where the 5-year survival rate for childhood cancer has increased from $\approx 30\%$ in the 1960s to $\approx 80\%$ seen today (236), whereas it is estimated that over 50% of the childhood cancer survivors have received ANTs (144). Even though now half-a-century old, ANTs remain among the mainstays of the modern combination cancer therapy. Rather than being supplanted by various novel targeted agents, there is a tendency to combine them in various schedules to maximize the therapeutic response (206).

As seen in Figure 1, ANTs are composed of a rigid planar tetracyclic structure with adjacent quinone and hydroquinone moieties, a short side chain with a carbonyl group at C-13, and an aminosugar daunosamine attached by a glycosidic bond to the C-7 of the tetracyclic ring. DOX differs from DAU only by the presence of a C-14 hydroxyl group. EPI is an epimer of DOX differing only in the orientation of hydroxyl group on daunosamine. Idarubicin is a DAU analog that lacks a C-4 methoxy group (292).

For a long time since their introduction, the precise mode of ANT anticancer action has not been well defined. The first proposed mechanism was DNA intercalation (185). The pla-

nar aromatic aglycone part of the molecule intercalates between two base pairs of the DNA, while the six-membered daunosamine sugar is positioned in the minor groove, and interacts with flanking base pairs immediately adjacent to the intercalation site (207). ANTs may also be toxic to cancer cells by reactive oxygen species (ROS) formation and site-specific DNA damage (190). Today, topoisomerase II α (TOP2 α) is generally recognized as the main target of ANT antitumor action (34). ANTs belong to the TOP2 poisons, a group of cytotoxic agents stabilizing a reaction intermediate in which DNA strands are cut and covalently linked to tyrosine residues of TOP2, eventually impeding DNA resealing. Failure of relaxing the supercoiled DNA results in block of DNA replication and transcription. Double-strand DNA breaks could ultimately then trigger apoptosis of cancer cells, apparently *via* the p53-dependent pathway (220).

ANTs are administered strictly by intravenous infusions. They are known for their large volumes of distribution ($\sim 800 \text{ L/m}^2$ for DOX) due to the wide distribution of the drug into the tissues and their binding within the intracellular compartment. Marked intracellular accumulation can result in concentrations 10–500-fold higher than extracellular drug levels, and this corresponds with considerably long terminal

FIG. 1. Chemical structures of the most important anthracycline antibiotics and mitoxantrone.

half-life of elimination (24–50 h). DOX is ~75%–80% plasma protein-bound, and plasma clearance is mediated mostly through hepatic metabolism and biliary excretion (75).

With respect to adverse/toxic effects, myelosuppression predominantly leading to neutropenia is the major dose-limiting complication of ANT-containing chemotherapy (75). Nausea, mucositis, diarrhea, and alopecia are common, but reversible. Accidental extravasation of the drug during administration can cause severe necrosis of affected tissue (75). The main complication associated with ANT treatment is however the risk of irreversible life-threatening cardiomyopathy and congestive heart failure (CHF) (75).

ANT-Induced Cardiotoxicity

Classification, incidence, and risk factors

ANTs are clearly the most dangerous anticancer drugs with respect to cardiovascular toxicity and are now perceived as the prototypic drugs responsible for Type I of chemotherapy-induced cardiac dysfunction (60). This type of cardiotoxicity is characterized by mostly irreversible morphological changes and cell death, which differ considerably from largely reversible Type II cardiac dysfunction induced by trastuzumab or tyrosine kinase inhibitors (60).

While undetected during preclinical animal studies (101), cardiotoxicity of ANTs has been first documented during early clinical evaluations of DAU (261) or DOX (22, 156). In 1979, the seminal study by Von Hoff *et al.* demonstrated cumulative ANT dose as the key risk factor for cardiotoxicity development (284). This study recommended a cutoff for DOX at a cumulative dose of 550 mg/m², based on a perceived relatively low incidence of cardiotoxicity ($\leq 7\%$) in doses up to that level (284). However, in 2003, a meta-analysis by Swain *et al.* found that an estimated 26% of patients would experience DOX-related manifest CHF at a cumulative dose of 550 mg/m² (258). Furthermore, data from the Childhood Cancer Survivor Study showed that as little as 100 mg/m² of DOX might cause a trend toward an increased risk of detectable asymptomatic abnormalities, whereas 270 mg/m² of DOX induced a measurable 4.5-fold excess risk of such abnormalities (119). Today, ANT cardiotoxicity is viewed as a multifactorial process that primes the heart to a life-time risk of systolic and/or diastolic dysfunction. The ANTs may interact and eventually synergize with comorbidities, unfavorable lifestyle, and cardiovascular toxicity of other anticancer drugs (182). Therefore, additional risk factors such as hypertension, early or advanced age, obesity, diabetes mellitus, coronary artery disease, prior irradiation, exposure to other cardiotoxic drugs, or prior heart failure have been defined (59, 294).

Several types of ANT cardiotoxicity have been recognized with a rather variable classification (62, 116, 131, 296): Acute cardiotoxicity occurs during or soon after the ANT administration (116, 131). It is often subclinical, but vasodilatation with hypotension and transient cardiac rhythm disturbances may be observed (116, 131). These changes are usually not dose dependent, resolve spontaneously, and do not preclude further ANT use (62). In addition, no connection to chronic ANT cardiotoxicity has been established (72, 185). Pericarditis–myocarditis syndrome may occur within 1–3 days; however, it was particularly seen in early trials employing high individual doses of ANTs and is uncommon today (27, 83). Clinically, the most significant are the chronic forms of ANT cardiotoxicity

with the early- and late-onset manifestations. The early-onset form develops later in the course of the chemotherapy or within the first year after its completion. It is typically characterized by development of left ventricular (LV) systolic dysfunction, which progresses toward dilated cardiomyopathy and CHF (116, 131). Histopathological hallmarks of the ANT cardiotoxicity are found predominantly in the left ventricle and interventricular septum, and consist of distension of the sarco-plasmic reticulum, cytoplasmic vacuolization within the myocytes, mitochondrial swelling, myofibrillar disarray, and eventual loss (62). These latter ultrastructural changes were quantitated by Billingham *et al.* and later by Mackay (21, 174). The second category of the chronic ANT cardiotoxicity is the late-onset (or delayed) form. It was described at the beginning of the 1990s among survivors of childhood cancers (76, 167, 253), and it is now well established that ANT cardiotoxicity may manifest even decades after the anticancer treatment (235a).

Chronic forms of ANT-induced cardiotoxicity are associated with poor prognosis, and patient survival seems to be worse than in other types of CHF (61). At present, there is no specific evidence-based treatment of ANT-induced cardiotoxicity (159), and the treatment follows the guidelines for chronic HF. Angiotensin-converting enzyme inhibitors (ACEI) and β -adrenergic receptor-blocking drugs (β -blockers) may be used already upon asymptomatic drop of the LV systolic function (159). For patients with end-stage CHF, heart transplantation remains the last option (268).

In addition, there is a considerable interindividual variability in the susceptibility to chronic ANT cardiotoxicity. Some patients develop cardiotoxicity at a total cumulative ANT dose of 300 mg/m² or even lower, whereas some early studies suggested that some patients had no significant cardiac complications despite achievement of the doses as high as 1000 mg/m² (284). These findings strongly suggest the involvement of a genetic component and pharmacogenomic approach pointed to a potential role for polymorphisms in several candidate genes that include carbonyl reductase 3, glutathione S-transferase, multidrug resistance proteins 1 and 2, or NAD(P)H quinone oxidoreductase (48).

Cardiac assessment before, during, and after the ANT-containing treatment is essential. Among the first approaches employed for sensitive and reliable detection of the chronic ANT cardiotoxicity was the endomyocardial biopsy (21). However, its invasive nature hinders and in fact nearly prevents its routine use in modern clinical practice. Current recommendations for cardiac monitoring of ANT-treated patients are thus mostly based on the noninvasive examination of the LV systolic function, since its decline is a well-known hallmark of ANT cardiotoxicity (129). Echocardiographic assessment of diastolic function has been reported as a more sensitive tool for the detection of asymptomatic early myocardial damage (70). Furthermore, selective biochemical markers of myocardial damage (particularly cardiac troponins T and I and natriuretic peptides such as NT-pro-BNP) are also valuable for early detection of cardiotoxicity (180, 225).

ANT-induced cardiotoxicity can be influenced by concomitant application of other anticancer drugs. Trastuzumab, a humanized monoclonal antibody against the HER2 (human epidermal growth factor receptor 2, also known as *c-erbB-2* or *neu*), is an important component of current chemotherapy protocols for women suffering from HER2-positive breast cancer. However, its use has been associated with a higher

incidence of symptomatic or asymptomatic cardiac dysfunction that is apparently related to interference with HER2-dependent prosurvival signaling in the cardiomyocytes (73). Even though the trastuzumab-related cardiotoxicity is far less dangerous than that of ANT, their concomitant use is associated with CHF development at significantly lower cumulative ANT doses (73). Furthermore, ANT cardiotoxicity can be exacerbated also by chemotherapeutics that possess limited cardiotoxicity *per se*, such as in the case of concomitant administration of paclitaxel (73).

Strategies for cardiotoxicity prevention

In the light of difficult treatment, there has been a continuous effort to prevent or reduce the risk of cardiotoxicity development (296). The most effective, simple, and widely employed tool to prevent the ANT-induced cardiotoxicity is the limitation of cumulative ANT dose (258, 296). For each ANT, there are now recommended total cumulative doses that may be exceeded only with very careful cardiac monitoring (2) and/or pharmacological cardioprotection. However, lower ANT doses may imply the risk of lower cancer response rate, and considerable interindividual variability hinders reliable risk prediction in individual patients. Furthermore, it is increasingly recognized that there are no entirely safe ANT cumulative doses (258).

Over the past five decades, more than 2000 modified ANT chemical structures have been synthesized and tested. The main effort was to reduce cardiotoxicity while retaining their unique cytostatic effectiveness. While several ANT derivatives have been evaluated in clinical trials (*e.g.*, amrubicin or pirarubicin), only EPI and idarubicin received approval for clinical use. Unfortunately, clinical trials have not confirmed lower cardiotoxicity of idarubicin as compared to DAU (16, 198). In some chemotherapy regimens, EPI is favored over DOX due to the perceived lower risk of cardiac injury. However, as EPI is administered in higher individual and cumulative doses, there is a question that a distinct difference between these two drugs exists at the equipotent doses (67). Despite the limited success, the search for less-cardiotoxic ANTs still continues.

The next important strategy to ameliorate the risk of ANT cardiotoxicity is the modification of ANT administration. Several reports have suggested that continuous infusion with reduced peak ANT concentrations is associated with a lower risk of cardiotoxicity than administration as a bolus (157, 235d). However, literature is not conclusive, as several studies failed to find a relationship between the infusion duration and cardiotoxicity risk (161, 168, 251). Another popular and widely tested strategy is to alter the pharmacokinetics (but also pharmacodynamics) of ANTs by their passive targeting into the tumors that may reduce myocardial exposure. This can be achieved by liposomal encapsulations of the drugs, and such delivery systems are available for DAU (DaunoXome™) as well as DOX (Myocet™, Caelyx™, and Doxil™). These formulations have distinct properties, such as stability, drug-release rate, plasma half-life, sites of deposition of the liposome, or toxicity profiles (160). Several controlled trials have been published that demonstrated a lower overall risk of cardiotoxicity of liposomal ANTs in adults (14, 197). In children with cancer, several observational studies described the use of liposomal ANTs, but no randomized controlled trials have been reported. Hence, definite data on cardiac safety of

these formulations need longer follow-up of both cardiotoxic effects as well as the anticancer response (237). Of note, liposomal ANTs also have specific side-effects, such as allergic reactions and hand-foot syndrome, a dermatologic toxic reaction that can lead to considerable discomfort (82). Finally, the method for ANT cardiotoxicity prevention with the strongest evidence from clinical trials is the pharmacological cardioprotection with dexrazoxane (DEX) (257).

Experimental models of ANT-induced cardiotoxicity

Clearly, the best and the most relevant data should be obtained from randomized controlled clinical trials. However, regarding cardiotoxicity assessment, one may usually evaluate only noninvasive parameters, as human myocardial biopsy or necropsy samples are hard to obtain. Furthermore, the majority of cancer patients are treated with multidrug regimens, which together with overall heterogeneity of their clinical picture make the interpretation of clinical data troublesome. Some approaches are also either ethically or practically unfeasible in clinical settings. Therefore, the use of experimental model systems is unavoidable.

In all nonclinical studies, the selection of an appropriate experimental model is an essential point determining translatability of research outcomes into clinical medicine. The simplest are cell-free *in vitro* experiments, such as with combinations of chemicals in buffered solutions, purified proteins, or subcellular fractions (*e.g.*, microsomes or mitochondria). Very common is then the use of cellular models using isolated cardiac myocytes—mostly, primary neonatal rat cardiomyocytes (10, 89, 112, 146), and less often, adult cardiomyocytes (136). During the last decade, studies with immortalized cardiomyocyte-derived cell lines (in particular the H9c2 rat embryonic cardiomyoblasts) have emerged (138, 186, 279). *Ex vivo* studies often use isolated atria (although these are not a major target for ANT cardiotoxicity), papillary muscles, or whole-heart preparations perfused according to Langendorff (217). It should be noted that the majority of these biological models enable only limited time of exposure, which hinders simulation of the chronic ANT cardiotoxicity. In addition, increasing ANT concentrations to supratherapeutic levels help to achieve distinct toxicity, but again, it may hinder translatability of such data to *in vivo* settings. For *in vivo* studies, mouse, rat, rabbit, pig, and dog have been the commonly used animals (101). Importantly, these whole-animal experiments enable repeated administration of ANTs and chronic cardiotoxicity development, relevant to what is seen in clinical practice (71, 101, 139, 239). Nevertheless, numerous studies have unfortunately used regimens where animals were treated only with single or few very high ANT doses. The outcomes from these studies have to be treated cautiously. Not only there is a risk of oversimplification, but also importantly, the induced myocardial impairment need not share many common denominators with the chronic ANT cardiotoxicity feared in clinical practice (242).

Molecular mechanisms of ANT-induced cardiotoxicity

Despite the four decades of vigorous research, the pathophysiology of ANT-induced cardiotoxicity is still not fully understood, and it is a subject of debate and considerable controversy (11, 35d, 72, 131, 184, 185, 235a, 312). The prevailing and traditional hypothesis is linked to an

iron-catalyzed induction of cardiac oxidative stress (242) and will be discussed in more detail in the following sections. In addition, multiple other possible mechanisms have been proposed such as impairment of calcium homeostasis (250) that can be related to direct effect of either ANT or their more polar hydroxyl metabolites (183). The calcium overload may lead to sarcomere disruption due to the calpain-dependent degradation of titin, a giant myofilament protein, crucial for force modulation in the myocytes and a scaffold for assembly of myofilamentous proteins (164). Some other suggested cardiotoxicity mechanisms include, for example, impaired gene expression of various important cardiac proteins (25), dysregulation of protein degradation by the ubiquitin-proteasome system (247), induction of mitochondrial DNA lesions (154), or interference with TOP2 (173) (Fig. 2).

ANT-induced ROS production

ANTs are well known for their ability to produce ROS through multiple pathways (116, 137, 242) (Fig. 3). First, one-electron reduction of ring C of the ANT tetracycline leads to the

formation of a semiquinone free radical. Its unpaired electron can be donated to oxygen forming superoxide radicals ($\bullet\text{O}_2^-$). Suitable flavoproteins catalyze the formation of reduced semiquinone radicals by accepting electrons from NADH or NADPH and passing them to ANT in a sequence of reactions known as the redox cycling. The dismutation of $\bullet\text{O}_2^-$ to hydrogen peroxide (H_2O_2) is catalyzed by superoxide dismutase (SOD) or may occur spontaneously. H_2O_2 is a relatively stable and low-toxicity molecule, and under physiological conditions is eliminated by catalase or glutathione peroxidase. However, H_2O_2 and $\bullet\text{O}_2^-$ may generate highly reactive and toxic hydroxyl radicals ($\bullet\text{OH}$). This takes place during the Haber-Weiss reaction, which is very slow unless catalyzed by transition metals—especially iron (84).

Thomas and Aust have shown that ANT may increase the amount of free redox-active iron by generating $\bullet\text{O}_2^-$, which mediates an iron release from ferritin (267). The formed $\bullet\text{OH}$ has a very short half-life and extreme high reactivity and toxicity. It reacts with any oxidizable compound in its vicinity and thus can induce damage to all types of macromolecules, including lipids, nucleic acids, and proteins (84).

FIG. 2. Overview of molecular changes associated with development of anthracycline cardiotoxicity. Green color indicates increase, whereas red color illustrates decrease due to the treatment. A, anthracycline; CK, creatine kinase; Cr, creatine; Cyt c, cytochrome c; MLC, myosin light chains 1 and 2; MMPs, metalloproteinases; PCr, phosphocreatine; RyR, ryanodine receptor; SERCA, sarco-/endoplasmic reticulum Ca^{2+} -ATPase; SR, sarco-/endoplasmic reticulum; ROS, reactive oxygen species; TOP2, topoisomerase II; VIM, vimentin; UBI, ubiquitin. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars.)

FIG. 3. Schematic illustration of main pathways of anthracycline-induced and iron-catalyzed oxidative stress production. Fe, iron; Fp, flavoprotein; GSH, reduced glutathione; GSSG, oxidized glutathione; H₂O₂, hydrogen peroxide; NAD(P), nicotinamide adenine dinucleotide (phosphate); •O₂⁻, superoxide radical; •OH, hydroxyl radical; SOD, superoxide dismutase.

The second basic mechanism by which iron may promote the oxidative stress induced by ANTs is *via* the formation of ANT-Fe complexes (137). In the presence of a reducing system (NADH cytochrome P450 reductase or thiols, such as cysteine or glutathione), the ANT-Fe³⁺ complex is reduced to ANT-Fe²⁺, which can react with O₂ to form •O₂⁻, which in turn dismutates to H₂O₂ and/or enters the Haber–Weiss reaction, resulting in •OH. Alternatively, ANT-Fe²⁺ can react with H₂O₂ yielding directly •OH. In the absence of reducing systems, ANT-Fe³⁺ can reduce its chelated iron by an intramolecular redox reaction, by oxidation of either the side chain on C-9 or the hydroquinone moiety at ring B, forming a free radical •ANT-Fe²⁺. In the presence of O₂, this complex is oxidized, yielding •O₂⁻ and •ANT-Fe²⁺ (116, 137, 242). Furthermore, apart from the ROS, cardiac exposure to ANTs may be also connected with the deregulation of the nitric oxide (NO) network. Overproduction of ROS and NO yields reactive nitrogen species (RNS), particularly the powerful oxidant—peroxynitrite (ONOO⁻) (64).

Involvement of iron in the ANT-induced oxidative stress and cardiotoxicity has been supported by rich experimental evidence as reviewed in detail elsewhere (242). Already in the early 1980s, Myers *et al.* have shown formation of the ANT-Fe complexes and resulting potentiation of oxidative damage of biomembranes *in vitro* (194). The ANT-Fe complex-mediated damage could not be blocked by classical ROS scavengers. Later on, augmentation of ANT cardiotoxicity by iron has been demonstrated in isolated rat cardiomyocytes, where lactate dehydrogenase (LDH) release and changes in cell contractility have shown a marked augmentation of DOX toxicity by prior iron loading (111). *In vivo*, using DOX-treated rats, iron loading resulted in severe weight loss and a twofold increase in the rate of mortality (166). In both studies, the unfavorable effects of iron on DOX cardiotoxicity could be eliminated by the iron chelator deferoxamine (DFO).

Substantially increased DOX cardiotoxicity by dietary iron loading in rats was also reported by the study of Panjra *et al.*, concluding that body iron stores as well as iron bioavailability in tissue may be important independent predictors of susceptibility to DOX cardiotoxicity in man (204). Miranda *et al.* have shown that *Hfe*-deficient mice (a model of human hereditary hemochromatosis, a disorder resulting in body iron overload) exhibited significantly greater sensitivity to DOX-induced cardiotoxicity. Increased mortality rate after chronic DOX treatment was observed in both *Hfe*^{-/-} and *Hfe*^{+/-} mice compared with wild-type animals. DOX-treated *Hfe*^{-/-} mice had a higher degree of mitochondrial damage and iron deposits in the heart than did the wild-type mice (187).

ANT-induced formation of ROS/RNS within the cell context

The investigation on intracellular sites of ANT redox cycling and production of ROS/RNS pointed to a potential involvement of the mitochondria, sarcoplasmic reticulum, perisarcoplasmic space, and cytoplasmic compartments (Fig. 4). Although the flavin-containing reductases are located in all these compartments, mitochondria have attracted the main interest. Nevertheless, the involvement of NADP oxidases (Nox) located in the cytosol and attached to the sarcolemma cannot be excluded (309).

ANT cardiotoxicity, ROS, and mitochondria. Mitochondria are among the most important sources of ROS under both physiological and pathological conditions (192). Hence, ANT-induced ROS production was quickly attributed to the mitochondria. In addition, unlike other organelles, mitochondria contain their own genome, which is quite prone to oxidative damage, and this has been also linked to ANT toxicity development (19, 155). The connection between ANTs and

FIG. 4. Anthracycline-induced reactive oxygen/nitrogen species production within the cell context. Black panels—anthracycline redox-cycling sites; gray panels—antioxidant defense. I, II, III, and IV, respiratory chain complexes; ANT, anthracyclines; CAT, catalase; GPx, glutathione peroxidase; GR, glutathione reductase; GSH, reduced glutathione; GSSG, oxidized glutathione; H_2O_2 , hydrogen peroxide; NAD(P) , nicotinamide adenine dinucleotide (phosphate); $\text{NO}^{\bullet}$, NO radical; NOS, NO synthase; Nox, NADPH oxidase; $\text{O}_2^{\bullet-}$, superoxide radical; $\text{OH}^{\bullet}$, hydroxyl radical; ONOO^- , peroxynitrite; SOD1, cytosolic superoxide dismutase (CuZnSOD); SOD2, mitochondrial superoxide dismutase (MnSOD); TrxR, thioredoxin-reductase; Trx-S_2 , oxidized thioredoxin; Trx-(SH)_2 , reduced thioredoxin; XO, xanthine oxidase.

mitochondria is not only mechanistic. ANTs possess a high affinity for cardiolipin, a negatively charged phospholipid of the inner mitochondrial membrane (77). Thereby, ANTs are retained at high concentrations in the mitochondrial compartment, particularly in the proximity of cardiolipin-associated proteins, such as the NADH dehydrogenase—complex I. Mitochondria have been repeatedly suggested as the most important target for ANT cardiotoxicity (18, 43, 175, 271, 285), and similar results have been also suggested by recent unbiased proteomic and phosphoproteomic investigations (Fig. 5) (79, 254).

ANTs have been reported to directly and indirectly interact with mitochondrial oxidative phosphorylation. *In vitro*, ANTs increase basal (state 4) respiration (78), which is explained by electron-accepting properties of the ANT molecule, causing partial diversion of electrons from the respiratory chain (18). This process results into one-electron reduction of the ANT molecule to the semiquinone radical with subsequent production of $\text{O}_2^{\bullet-}$ as described above. Further experiments identified that this process takes place at complex I of the respiratory chain, and this site has been proposed as the most important site for ANT redox cycling within the cardiomyocytes (43, 44, 52). The ANTs interact with the electron flow through complex I proximally to the rotenone-binding site (285), but molecular details of this interaction remain obscure.

Complex I is not only the major source of ROS but also an important target of their toxic action. This has been found not only in acute cardiotoxicity models (302), but more importantly, also in several well-established chronic ANT cardiotoxicity models (199, 201, 254). Furthermore, there are some indices that complex I impairment could be an early event preceding CHF development (199). ANTs may also impair the

function of other components of the respiratory chain as reviewed in detail by others (271). However, it is unclear whether these components are primary targets for ANT cardiotoxicity or mere consequence of previous perturbation in the electron transport chain or induced by elevated mitochondrial ROS due to the ANT redox cycling at complex I (18). Furthermore, some of these effects have been found only in rather high (supratherapeutic) doses or concentrations of ANTs, and thus their clinical relevance is unclear.

Importantly, using a chronic ANT cardiotoxicity model, Serrano *et al.* have described that ANTs induce a cumulative oxidative damage to mtDNA, and the change was detectable several weeks after the treatment (235b). Furthermore, Adachi *et al.* have shown that chronic ANT cardiotoxicity is associated with deletion mutations in mtDNA, which appeared to be at least partially oxidative stress dependent (1). Using low individual and total cumulative doses (DOX 1 mg/kg, weekly for 7 weeks) and a long follow-up period (30 weeks), Lebrecht *et al.* have reported a decrease in mtDNA/nDNA content and presence of common deletion mutations in mtDNA in rat hearts (153). These authors also found a relative decrease in activity of complex IV along with impaired expression of mtDNA-encoded complex IV subunits at this timepoint. Interestingly, these changes were not significant a week after the last drug administration, which highlights the importance of the time factor.

ANT-induced qualitative and quantitative mtDNA lesions with subsequent impairment of expression or compromised functionality of mtDNA gene products may explain the perpetuation of tissue damage for weeks, months, or even years after the exposure to drug (19, 155). Considering that mtDNA encodes 13 subunits of the respiratory chain, long-lasting

dosing (5 mg/kg, weekly for 5 weeks, and 5-week follow-up) (178). Of note, these changes preceded a significant decline of the LV systolic function.

Both decreased mtCK expression and activity may result in seriously impaired energy channeling, especially when it has been demonstrated that ANT treatment may disrupt expression and function of adenine nucleotide translocase-1 (ANT1) (254, 286), which is in a functional complex with smtCK at the inner mitochondrial membrane. In addition, impaired energy channeling may have a significant downstream negative effect, due to the inadequate stimulation of the mitochondrial respiration, and further exacerbate the failure to meet the energy requirement of the cardiomyocytes.

ANTs have been shown to have a profound impact on mitochondrial superoxide dismutase (MnSOD, SOD2), a manganese-containing enzyme located within the mitochondrial matrix. This enzyme is responsible for prompt conversion of mitochondrial $\bullet\text{O}_2^-$ to H_2O_2 , which is less reactive, and better crosses cell membranes. Interestingly, Li and Singal have shown that repeated ANT treatment (DOX 2.5 mg/kg, six doses over 2 weeks) markedly downregulates expression of MnSOD both at mRNA and protein levels and decreases its enzymatic activity 1 to 24 h after the last ANT dose with persistence for up to 3 weeks (162, 163). Similar outcomes have been reported from a proteomic analysis of chronic DAU-induced cardiotoxicity (3 mg/kg, weekly for 10 weeks) (254). This finding may also imply that oxidative stress can be substantially compartmentalized in ANT cardiotoxicity, as ANT-induced $\bullet\text{O}_2^-$ produced within mitochondrial matrix cannot cross the inner mitochondrial membrane as easily as H_2O_2 . Furthermore, increased local concentrations of $\bullet\text{O}_2^-$ might also favor its interaction with NO to form extremely reactive peroxynitrite, which may in turn cause local nitrosative stress. Interestingly, ANT-induced nitrosative stress has been documented to modify MnSOD to diminish its enzymatic activity (263), and this could round up the inability of the mitochondria to face the increased stress. Further studies should demonstrate whether this takes place in the chronic ANT cardiotoxicity settings.

ANT-induced oxidative and nitrosative stress in the mitochondria may have numerous consequences. Not only they may deregulate mitochondrial respiration and bioenergetics, but it may also result in mitochondrial calcium overload, which has been described by several groups as reviewed elsewhere (151, 286). Mitochondrial matrix calcium overload has been well connected with mitochondrial permeability transition pore (mPTP) opening and depolarization of the inner mitochondrial membrane, which lead to ATP depletion and further oxidative stress aggravation (128). In addition, mPTP opening is associated with mitochondrial swelling, which has also been observed in electron microscopic studies of hearts suffering from ANT cardiotoxicity (21). Unfortunately, the in-depth study of mPTP opening in chronic ANT cardiotoxicity is complicated by the inability to simulate appropriately these conditions *in vitro* on one hand and potential selection bias toward ANT-damaged cells upon isolation of the cells from chronically treated animals on the other hand.

Mitochondrial swelling can result in rupture of the inner mitochondrial membrane and release of apoptosis-inducing proteins. The latter event may be also triggered by the proapoptotic Bcl-2 family proteins creating nonselective channels

in the mitochondrial membrane. Indeed, clinically relevant doses and concentrations of ANTs have been repeatedly shown to activate apoptotic pathways (8, 196, 208, 226, 301), and successful cardioprotection with DEX has reduced this process (208). Hence, mitochondrial oxidative stress as well as other above-described events may trigger apoptotic cell death, which may be coresponsible for CHF development. Although, mitochondrial autophagy is likely to take place in ANT cardiotoxicity, and one cannot exclude its impaired regulation, as very little is known so far about involvement of this process in chronic ANT cardiotoxicity (246). Quite obscure is also the role of mitochondrial fission and fusion as well as mitochondrial biogenesis. Hence, all these processes deserve further studies preferably using chronic models, as this investigation may provide more complex and significant insights into the global picture of the chronic ANT cardiotoxicity.

ANT-induced ROS production outside the mitochondria. Besides mitochondrial complex I, other flavin-containing enzymes located outside the mitochondria have been implicated in ANT redox cycling, including NADPH oxidase, CYP450 reductase, or nitric oxide synthase (NOS) (50) (Fig. 4). Interestingly, the location of some of these enzymes matches with the location of ultrastructural damage to cardiomyocytes induced by chronic ANT cardiotoxicity.

Over the last decade, NADPH oxidase (Nox) has been suggested as one of the most important sources of ROS in the cardiovascular system. While five Nox isoforms have been distinguished, Nox2 and Nox4 are believed to play a major role in the heart, where they are bound to the sarcolemma of the cardiomyocytes (245). Wojnowski *et al.* have revealed that genetic polymorphisms in three cytoplasmic subunits of Nox2 make patients more prone to develop cardiotoxicity after the ANT treatment (295). However, only polymorphisms in p40^{phox} have been found associated with chronic ANT cardiotoxicity. In addition, using the Nox2^{-/-} mice, the authors have shown that genetic disruption of Nox2 protects the heart from LV dilation and systolic dysfunction induced by DOX (4 mg/kg, weekly for 3 weeks, and 5-week follow-up). Furthermore, using a similar DOX treatment, no significant changes in LV systolic and diastolic function, LV diameter, cardiac fibrosis, and Nox4 expression were found in Nox2^{-/-} animals (309). Mukhopadhyay *et al.* have detected no change in expression of Nox1, Nox2, and its regulatory subunits after single high-dose DOX treatment (20 mg/kg) (191). These authors also did not observe any effect of Nox inhibitors on DOX-induced toxicity in H9c2 cells (DOX 1 μM , 16 h exposure). However, Zhao *et al.* have found a marked increase in Nox2 and Nox4 expression at mRNA levels after repeated *in vivo* treatment (309). Although further studies are definitely needed, available data suggest that Nox might be implicated in chronic ANT cardiotoxicity development.

NADPH-P450 reductase is another flavin-containing enzyme implicated in ANT redox cycling (50). The intracellular location of this enzyme within the endoplasmic reticulum suggests its connection to pathological distension of the sarcotubular system, which is believed to be behind cytosolic vacuolization observed in chronic ANT cardiotoxicity. Liver microsomes rich in NADPH-P450 reductase have been shown effective in catalysis of ANT redox cycling and ROS production (9). However, Doroshow *et al.* have demonstrated 14-fold

lower relative effectivity of redox cycling induced by cardiac sarcosomes as compared to cardiac submitochondrial particles, which may diminish the importance of this pathway (50). Furthermore, genetic disruption of the NADPH-P450 reductase expression within the heart has been reported to show no protection against acute ANT cardiotoxicity (DOX 10–20 mg/kg) (50). As there is a lack of data from the chronic ANT cardiotoxicity models, one cannot draw a definite conclusion on involvement of this pathway in clinically important forms of cardiotoxicity. Nevertheless, available data do not argue for the key importance of this ROS generation pathway.

Besides the mitochondria and endoplasmic reticulum, important ANT redox cycling activity has been found also in the myocardial cytosolic fraction, and this has been mainly attributed to xanthine oxidase (50). Pan and Bachur have demonstrated that bovine milk xanthine oxidase can catalyze ANT redox cycling and ROS production (203). Using H9c2 cells, Mukhopadhyay *et al.* have found a significant increase in xanthine oxidase expression at the mRNA level after the DOX (1 μ M) treatment, whereas only an insignificant trend was detected at the protein level. However, allopurinol failed to provide significant protection from DOX-induced cell death under the same conditions (191). Quite surprisingly, there is a lack of *in vivo* data about its potential against chronic ANT-induced cardiotoxicity.

ANT redox cycling can be also promoted by NOS (278), and all three NOS isoforms are able to catalyze these reactions. Conflicting data have been published on the impact of genetic and pharmacological manipulation of activity of NOS isoforms on acute ANT cardiotoxicity models (35a, 37, 202, 289). Nevertheless, repeated dosing with DOX (3 mg/kg, weekly for 4 weeks, and 4-week follow-up) strongly suggested distinct roles of different NOS isoforms in ANT cardiotoxicity. While nNOS has been suggested to play rather a protective role, eNOS expression did not correlate with the cardiotoxicity severity. In wild-type animals, the authors have not found induction of NOS isoforms at the mRNA level due to the ANT treatment, whereas a gradual decrease of abundance has been shown in eNOS at the protein level along with decrease in NO production. Interestingly, despite a significant decline in systolic function and increase in the LV diameters after the chronic ANT treatment, the authors have not found an increase in lipoperoxidation. Although complex phenotype of animals with genetic manipulation of individual NOS isoforms may complicate the interpretations of data, it seems that NOS are not among the main catalysts of ROS production following the clinically relevant ANT doses (47).

ANT cardiotoxicity and myocardial antioxidant defense

Oxidative stress takes place when production of ROS/RNS oversaturates the capacity of cellular antioxidant defense (84). Of note, lower levels of physiological antioxidants such as catalase have been speculated as responsible for particular vulnerability of the heart to toxicity of ANT (53). Although many studies have examined the effects of acute and chronic ANT treatment on physiological antioxidants, it is very difficult to draw a definitive conclusion due to the enormous heterogeneity of models, tissue sampling times, and outcomes of these interventions. Unfortunately, genetically modified animals, which might shed a light on mechanistic importance of antioxidant defense and signaling cascades, have been

employed solely in acute ANT cardiotoxicity settings so far (69, 135, 298, 302, 303). Therefore, the translatability of these findings to clinically important chronic forms of ANT cardiotoxicity remains unsure.

As described above, chronic ANT cardiotoxicity has been associated with a marked drop in expression of the mitochondrial SOD isoform (163, 254). Interestingly, the CuZn-SOD (SOD1) isoform has not been found regulated in the similar manner in these studies, and therefore signaling pathways responsible for selective ANT-induced down-regulation of MnSOD deserve further study. Several studies have reported no significant change in total myocardial SOD activity due to chronic ANT treatment (5, 81, 218, 249). A role of MnSOD in ANT cardiotoxicity has been probed with transgenic mice overexpressing MnSOD. In these animals, a short-term treatment with supratherapeutic doses of DOX (10–25 mg/kg) has been found to induce less morphological ultrastructural changes (particularly in the mitochondria), and it preserved mitochondrial respiration (302, 303).

Several studies have found no change in expression and/or activity of myocardial catalase in chronic ANT cardiotoxicity models (5, 42, 81, 249), whereas others have found an increased activity of the enzyme due to the treatment (163, 218). The mechanistic role of catalase has been probed with the transgenic mice overexpressing the enzyme. Unlike the wild-type controls, transgenic mice with 60–100-fold higher myocardial catalase activity were found free of myocardial lipoperoxidation, elevation of total CK activity in plasma, and functional deterioration of the atria after the supratherapeutic dose of DOX (20 mg/kg). In contrast, transgenic animals with the highest (200-fold) activity in the heart showed similar results as the wild-type controls (135).

Different regulation of glutathione antioxidant system enzymes has been observed on chronic ANT cardiotoxicity models. Robison *et al.* (218) and Alderton *et al.* (5) have found no change of glutathione peroxidase activity a week or more after the chronic weekly ANT treatments, while others have reported a slight, but significant, increase at this time point (279). A persistent decrease of expression and activity of this enzyme has been reported from compressed chronic ANT cardiotoxicity models where a total cumulative dose of DOX (13.5–15 mg/kg) was administered over 2–3 weeks only (163, 215, 249). The involvement of glutathione peroxidase in acute ANT cardiotoxicity has been probed using genetically modified organisms (69, 298). While knockout of the enzyme has not affected sensitivity of the mice to acute *in vivo* treatment with high DOX dose (22.5 mg/kg), significant enhancement of the toxicity has been found in the hearts isolated from these animals and perfused with DOX (5 μ M) (69). Conversely, the overexpression of the enzyme protected the isolated hearts from toxicity induced by perfusion with DOX (5 μ M), and it showed cardioprotection against single high dose of DOX (15 mg/kg) (298). While some studies reported no change in glutathione reductase activity in the heart a week after repeated ANT treatment (279), others have shown either a slight decrease (81) or even a significant elevation of the activity (218).

Several authors have focused on examination of oxidized and/or reduced forms of glutathione in the myocardium after chronic ANT treatment. Some studies have reported no change in availability of reduced glutathione or unaltered GSSG/GSH ratio within the myocardium a week after chronic ANT treatment (5, 279) despite the cardiomyopathy

development. One of these studies examined also a functional role of glutathione in ANT toxicity *in vitro* using H9c2 cells exposed to DAU (0.1–10 μ M). While a decrease of cellular glutathione content induced by preincubation of the cells with buthionine sulfoximine (BSO) sensitized the cells toward H₂O₂ (60–1000 μ M) toxicity, it had no impact on the toxicity of DAU (279). Others have found either increase (218) or slight decrease of glutathione content after repeated *in vivo* ANT treatments (81).

Antioxidants As Cardioprotectants in ANT-Induced Cardiotoxicity

As ANT-induced cardiotoxicity has been hypothesized to be linked with oxidative stress, many classic as well as novel antioxidants have been tested *in vitro* or using acute cardiotoxicity models *in vivo* with reported positive outcomes in most of cases. Such investigation has been performed with vitamin A (265), vitamin C (66), vitamin E (288), *N*-acetylcysteine (195), amifostin (126), a metalloporphyrine peroxynitrite decomposition catalyst (202), different flavonoids (223), and many others. However, direct translatability of such data into clinical medicine might be an issue, as the acute ANT cardiotoxicity is rarely clinically significant, and extrapolation to chronic ANT cardiotoxicity may be skewed by employment of supratherapeutic doses/concentrations, lacking the factor of time and absence of reactions associated with repeated exposure (72).

Numerous antioxidants have been also studied using different chronic ANT cardiotoxicity models with considerably less positive outcomes, especially when long-term DEX-validated animal models were employed. Furthermore, many findings were contradictory to the outcomes described from acute ANT cardiotoxicity models. This includes negative findings on cardioprotection with vitamin E (17, 26, 277), *N*-acetylcysteine (102, 272), and amifostin (107, 216). Interestingly, although Berthiaume *et al.* have found suppression of DOX-induced oxidative stress due to the dietary supplementation of vitamin E, the treatment has little-to-no effect on the cardiotoxicity parameters (17). In addition, while significant protection has been found in two flavonoid derivatives (mono-HER and frederine) (273, 274), further experiments showed that cardioprotective effects lose their power after longer follow-up (29). Although vitamin C has been suggested to decrease the mortality rate induced by both acute and subchronic DOX treatment, cardioprotective effects have been evaluated against repeated ANT treatment only in a very low DOX cumulative dose (2 mg/kg) (66). Moderate experimental evidence has been found on cardioprotective effects of ebselen, L-carnitine, propionyl L-carnitine, catechin, and melatonin (143, 181, 222, 227, 300). However, these data may deserve further confirmation on long-term models using multiple cardiotoxicity parameters. Significant cardioprotective effects have been repeatedly documented in probucol (162, 179, 248, 249). However, El-Deemerdash *et al.* have suggested that probucol may interfere with the DOX pharmacokinetics in terms of increasing total clearance of the drug (56), which should be further verified. Unfortunately, mostly, these experimental agents have not been directly compared to DEX (see below) to estimate their cardioprotective potential and confirm the validity of the model used.

Interestingly, a significant cardioprotection has been described on the compressed chronic ANT cardiotoxicity model

(DOX 2.5 mg/kg, six doses over 2 weeks, and 3-week follow-up) with carvedilol, a beta-blocker with vasodilatory and antioxidant properties (179). The protective effects were not found in atenolol, which suggests that cardioprotection can be β_1 -receptor independent. These findings have been confirmed further by others on the models utilizing weekly DOX dosing (2 mg/kg for 7 weeks) (200, 224), and these investigations showed that the cardioprotective potential of this agent may be connected with the preservation of mitochondrial function and prevention of mitochondrial calcium overload.

Data from clinical trials have also yielded negative results regarding the cardioprotective potential of several antioxidants, namely vitamin E (158), *N*-acetylcysteine (54, 193), or mono-HER (28). Although these agents have been so far tested in rather small clinical trials with numerous imperfections, accumulating body of evidence argues against the value of these agents as clinically effective cardioprotectants in ANT cardiotoxicity settings.

Of note, relatively encouraging results have been reported from a clinical trial with carvedilol (133). Here, the potential cardioprotective effects of carvedilol (12.5 mg orally on the daily basis) were investigated in 25 patients undergoing ANT-based chemotherapy. Interestingly, while control patients showed significant worsening of both systolic and diastolic cardiac performance after DOX or EPI (cumulative dose 525 and 788 mg/m², respectively), the carvedilol-treated patients were free of significant changes. These optimistic findings merit further study in large randomized controlled trials with longer follow-up.

DEX-Afforded Cardioprotection Against ANT Cardiotoxicity

DEX (ICRF-187, ADR-529) and the corresponding racemic mixture—razoxane (ICRF-159, ADR-159)—belong to bis-dioxopiperazine agents originally developed by Creighton *et al.* as potential anticancer agents (39). The authors aimed to find cell-permeable EDTA prodrugs that may target biomolecules of vital importance within the cancer cells. However, anticancer effects of DEX and razoxane have been later attributed to TOP2 inhibition (36, 262). Razoxane has passed through extensive preclinical development as an anticancer drug. However, it has never advanced beyond clinical trials.

Herman *et al.* has initiated research on potential cardioprotective effects of DEX and razoxane (105), but most of later studies preferred DEX due to the better solubility. Despite the intensive research, a mechanism of cardioprotective effects of DEX against ANT-induced cardiotoxicity is not completely understood. However, the most accepted hypothesis proposes the key role to iron chelation properties of a hydrolytic product of the drug with subsequent prevention of myocardial oxidative stress (41, 87). DEX had passed all the stages of preclinical and clinical research and has been finally approved in Europe and the United States for cardioprotection in patients treated with ANTs (CardioxaneTM and ZinecardTM) with several generic preparations recently available (ProcardTM and CardynaxTM). More recently, DEX has been also approved for treatment of accidental extravasation of ANTs (SaveneTM).

Chemistry

DEX is a (+)-(S)-enantiomer of racemic 1,2-bis-(3,5-dioxopiperazine-1-yl) propane (razoxane). Racemic razoxane

FIG. 6. Chemistry of dexrazoxane (ICRF-187). (a) Stepwise hydrolysis of dexrazoxane to intermediate metabolites B and C and iron-chelating metabolite ADR-925. (b) Chemical structure of complexes of ADR-925 with Fe³⁺.

is poorly soluble in water, which precluded preparation of intravenous formulation, and therefore this drug was available only for oral administration. Unfortunately, dose-dependent fluctuations in razoxane bioavailability complicated its therapeutic use (38). Nevertheless, Repta *et al.* have observed nearly five-times higher solubility of DEX, which enabled intravenous formulation of the drug and resolved the pharmacokinetic issues (214).

In aqueous solutions of physiological pH and temperature, DEX undergoes chemical hydrolysis of dioxopiperazine rings with a half-life of 9.3 h (85) (Fig. 6a). This reaction yields intermediates with only one ring opened (B and C), which then hydrolyze further to a final product—a diamide of EDTA (ADR-925) (Fig. 6a). Interestingly, multivalent ions may facilitate the hydrolysis of DEX and its intermediate degradation products. Fe³⁺ has been shown to increase hydrolysis of DEX, whereas Fe²⁺ is particularly effective in promoting hydrolysis of one-ring-opened hydrolytic intermediates to the ADR-925. Significant enhancement of the latter reaction has been also demonstrated for physiological concentrations of Mg²⁺, Ca²⁺, Mn²⁺, Cu²⁺, or Zn²⁺ (87).

Chelating properties of DEX hydrolysis products

ADR-925, a product of total hydrolysis of DEX, has a significant affinity to both Fe²⁺ and Fe³⁺ with formation constants 10¹⁰ M⁻¹ and 10¹⁸ M⁻¹, respectively. Indeed, EDTA, which is lacking a diamide moiety, is a several-order-of-magnitude stronger iron chelator with the Fe²⁺ and Fe³⁺ formation constants 10¹⁴ M⁻¹ and 10²⁴ M⁻¹, respectively. Nevertheless, ADR-925 is still relatively a strong hexadentate iron chelator (Fig. 6b) that chelates iron in a similar manner as EDTA, and the same applies on hydrolytic products of other bisdioxopiperazines (49). The resulting complexes [Fe(ADR-925)H₂O]⁺ and [Fe(EDTA)H₂O]⁻ exhibit a distorted pentagonal bipyramidal geometry with the 7th coordination site on the Fe³⁺ center occupied by a water molecule (49). Of note, the

labile water molecule bound to iron is thought to explain the redox cycling capabilities of EDTA complexes and associated production of damaging hydroxyl radicals. The same properties have been described to be analogically applicable on the complex of iron with ADR-925 (49, 266).

ADR-925 is a stronger iron chelator than ANT_s, and thus it can effectively displace Fe³⁺ from the complex with these drugs. Also, the intermediate hydrolysis products (B and C) have been identified to act as iron chelators, although only as tetradentate ones (32). They have been also shown to displace the iron from complexes with ANT_s, and the resulting complexes then hydrolyze further to form the ADR-925–iron complex. However, Thomas *et al.* have demonstrated that ANT semiquinone radicals drive redox cycling of racemic ADR-925 (ICRF-198) nearly as effectively as EDTA, and this process leads to production of •OH, which argues against simple displacement of iron from ANT–iron complexes as the main mechanism of cardioprotective action. It should be also noted that, similarly as EDTA, ADR-925 is far from being a selective iron chelator, as it has been found to bind also Cu²⁺, Mn²⁺, Zn²⁺, and Ca²⁺ with formation constants 10¹⁵, 10¹⁰, 10¹⁰, and 10⁷ M⁻¹, respectively, and one cannot exclude that it may be related to some of therapeutic effects of DEX (266).

General pharmacokinetics

In clinical practice, DEX is administered in a short (≈ 15 min) infusion, and its pharmacokinetics is best described by a two-compartment open model with first-order elimination kinetics (41). Clinically used doses of DEX (typically 500–1000 mg/m²) yield c_{max} of 136–280 μM (41). Plasma protein binding is negligible, and distribution into the tissues is relatively fast with a volume of distribution matching total body water, which implies significant penetration into the intracellular compartment. The plasma concentrations of DEX decline in two phases with a half-life of 15

and 140 min. The total body clearance is 0.29 L/h/kg, with renal excretion as a predominant route of elimination (42%–48% of a dose of DEX is recovered unchanged in the urine) (41, 55, 293). In experimental animals, the highest concentrations of the drug have been found in the kidney and liver 2 h after the DEX (12.5 and 100 mg/kg) administration, whereas the order-of-magnitude lower concentrations have been reported in the myocardium (94).

Metabolism and bioactivation

DEX is believed to be a prodrug that acts as a cardioprotectant through its chelating-active metabolite (41, 87). Hence, DEX metabolism and particularly its bioactivation within the heart are the points of key importance. Previously, a little attention has been paid to DEX metabolites in clinical studies, which may be due to the analytical difficulties with their selective and sensitive determination in biological matrices. Schroeder *et al.* (234) have shown detectable ADR-925 concentrations already at the end of DEX infusion (1000–1500 mg/m² over 15 min). The $c_{\max}$ ($\approx 30 \mu\text{M}$) was reached soon, and after 4 h plateau, a slow decline of ADR-925 concentrations occurred. The concentrations of the intermediates B and C reached their maximal concentrations very early and declined rapidly thereafter with half-lives 2.5 and 0.6 h, respectively. The maximal concentrations of the parent compound (211 μM) were much higher than those of metabolites (234).

Schroeder and Hasinoff have described the metabolism of DEX in rats. The authors have found a rapid metabolism of DEX with significant concentrations of all three metabolites in plasma, already 5 min after DEX administration (40 mg/kg, intravenously). The plasma concentrations of ADR-925 rose significantly to become comparable to DEX 60 min after the administration (232). The same investigators have determined the tissue concentrations of ADR-925 2.8 h after the administration of the same dose of DEX to rats (233). They found 51 $\mu\text{mol/kg}$ of wet tissue of ADR-925 in the rat heart, whereas almost double values were found in the liver. A complementary study on ADR-925 (20 mg/kg) pharmacokinetics has shown a short elimination half-life (8.3 min) and relatively low myocardial concentrations (7.4 $\mu\text{mol/kg}$ of wet tissue, 1.5 h after drug administration), which could imply limited distribution of the metabolite from the circulation (233). The latter finding rather suggested *in situ* bioactivation of DEX within the cardiomyocytes. Interestingly, the intermediates B and C were distributed to the heart much easier (233). Unfortunately, there is a lack of information on concentration–time profile of DEX and its metabolites in the heart. The PK/PD investigation with a focus on the heart may shed more light on importance of DEX metabolism for cardioprotective action.

The DEX metabolism has been also studied *in vitro* using cardiomyocytes, hepatocytes, tissue homogenate fractions, and purified enzymes. The majority of these experiments were performed in the Hasinoff's laboratory, and the authors have proposed that DEX undergoes stepwise hydrolysis by two tissue hydrolases—dihydropyrimidinase and dihydroorotase (87, 94). However, the dihydropyrimidinase, which is expected to hydrolyze DEX in the first step, has been shown absent in the heart, although it is abundant in other tissues, including the kidney and liver. Moreover, in contrast to porcine liver and kidney tissue and purified dihydropyrimidinase, the heart tissue fraction has been shown unable to hydrolyze DEX. In cell culture experiments, Schroeder *et al.*

have demonstrated a rapid and nearly complete decline of DEX concentrations in the medium containing hepatocytes with concomitant, but disproportional, raise of ADR-925 (235). However, the decline of DEX was apparently less profound when isolated neonatal ventricular cardiomyocytes were used. Unfortunately, ADR-925 was not examined in these experiments, and these cell culture studies have not shed light on the intracellular compartment, where the metabolites are formed, and when the active metabolites are thought to exert their chelating or other effects. Hence, the intracellular metabolism of ADR-925 deserves further study with focus on the relative rate of metabolism, subcellular localization, and potential retention of relatively polar metabolites inside the cardiac cells.

Hasinoff's group approached this issue indirectly through measurement of intracellular chelation within the cardiomyocytes after the incubation with DEX using an acetoxymethyl ester of calcein (86). Their data suggest that DEX indeed penetrates into the cardiomyocytes, and is only slowly converted there to the chelating metabolites, which contrasted with fast and significant intracellular chelation induced by 10-fold lower concentration of ADR-925. Although these experiments used rather specific experimental conditions, the results may argue against the role of metabolic bioactivation of DEX to ADR-925 within the cardiomyocytes. Further experiments are needed to clarify this point.

Cardioprotection against ANT cardiotoxicity in vitro

Sawyer *et al.* have published a seminal study showing that 10 μM DEX protects the neonatal cardiac myocytes from apoptotic cell death induced by clinically relevant DAU concentrations ($\leq 1 \mu\text{M}$), while it is unable to protect these cells from necrotic cell death induced by higher concentrations of DAU ($\geq 10 \mu\text{M}$) (226). Hasinoff's group has shown that DOX accumulates in the mitochondria and induces depolarization of the mitochondrial membrane potential at clinically relevant concentrations ($\leq 1 \mu\text{M}$). DEX preincubation (90 μM) was able to effectively prevent the latter mitochondrial changes. Relatively high DOX concentrations ($\geq 10 \mu\text{M}$) were also capable to significantly oxidize reduced dichlorofluorescein in cardiomyocytes, which was preventable by DEX pretreatment (90). However, the same group has shown that unlike the parent DEX molecule, neither the intermediate metabolites B and C nor ADR-925 is able to protect the neonatal cardiomyocytes from toxicity of 1.5 μM DOX (91). Of interest, using the calcein assay, more pronounced intracellular chelation has been found for both metabolites (ADR-925 and C) than for parent DEX. The authors have concluded that either DEX metabolites do not have an access to the critical iron pool within the cell, or other mechanisms might be involved in the cardioprotective effects of DEX (91).

Interestingly, the same group has shown that both DEX and ADR-925 can significantly protect isolated cardiomyocytes from hypoxia–reoxygenation damage, although ADR-925 was less effective (232). Furthermore, others have suggested that DEX may act as a scavenger of ROS without enzymatic hydrolysis to ADR-925, and its antioxidant effect may be iron independent (132). In addition, using H9c2 myoblasts and fibroblasts from TOP2 β knockout mice, Lyu *et al.* have

suggested that the parent compound DEX may be protective through inhibition of ANT-induced and TOP2 β -mediated DNA damage (173).

Cardioprotection against ANT cardiotoxicity in vivo

In the first *in vivo* studies, Herman *et al.* have shown that razoxane pretreatment (100 mg/kg) can partially decrease the mortality rate and ameliorate certain signs of acute cardiovascular toxicity induced by sublethal DAU doses (50 and 25 mg/kg) in Syrian golden hamsters (97, 104).

With recognition of clinical importance of chronic ANT cardiotoxicity, the interest has been shifted toward the animal models receiving repeated cycles of clinically relevant individual ANT doses. Again, Herman's laboratory has made a significant part of this pioneering job. With accumulating body of evidence, it has become firmly established that DEX is able to effectively protect the heart and cardiomyocytes from chronic ANT cardiotoxicity in various animal models, including rabbits, dogs, mice, normotensive and spontaneously hypertensive rats, guinea pigs, and pigs as reviewed elsewhere (101, 124).

Furthermore, it has also become obvious that DEX-afforded cardioprotection is applicable on cardiotoxicity of all studied ANTs, including DOX, DAU, EPI, idarubicin (101, 124), or mitoxantrone (109). Furthermore, using animal models, a dose-response of DEX cardioprotection has been established (125). It has been shown that DEX provides significant cardioprotection when administered at dose ratios (DEX/DOX) 4:1 to 30:1, and the ratio 10:1 to 20:1 has been selected as optimal for clinical studies (124, 125). Regarding the timing, in beagle dogs, it has been found that outcomes of the cardioprotective intervention are significantly better when DEX is administered simultaneously with DOX as compared to administration 2 h after the DOX administration (100). The time intervals between the DEX and DOX administration have been systematically evaluated of in mice (from 2 h before to 1 h after DOX). Both extremes were found inferior to other intervals, whereas administration 30 min before DOX has provided the best results (124). Importantly, Herman and Ferrans have clearly demonstrated that the DEX effect is not a mere delay of cardiotoxicity, but real long-lasting cardioprotection (99), and they have also shown that DEX pretreatment enables applications of much higher cumulative doses of DOX with a bearable risk of cardiotoxicity (103). To our best knowledge, there has been only one study that suggested a failure of DEX in cardioprotection against ANT cardiotoxicity (DEX 60 mg/kg administered to 10 days old rats before single DOX dose—3 mg/kg) (96). Nevertheless, others have demonstrated significant cardioprotection of DEX (20 mg/kg) against chronic DOX-induced cardiotoxicity (1 mg/kg, weekly for 7 weeks) in weanlings and young adults (46).

Interestingly, relatively limited data are available on mechanisms involved in DEX-afforded cardioprotection. An early study of Rajagopalan *et al.* has shown that 25 μ M DEX significantly reduces production of $\bullet$ OH in an isolated heart perfused with 1 μ M DOX (211). However, the production of $\bullet$ OH did not show common concentration-response relationship in the studied range (DOX 0.1–25 μ M), and it became significant only 10 to 15 min after the beginning of perfusion with the drug. Alderton *et al.* have not found any changes in total activity of myocardial superoxide dismutase, glutathi-

one peroxidase, catalase, and reduced glutathione after either acute (12 mg/kg) or chronic DOX dosing (1 mg/kg, weekly for 12 weeks), alone or with DEX pretreatment (5). Other authors have found no effect of DEX (40 mg/kg) on myocardial TBARS levels after acute EPI treatment (10 mg/kg) or gamma irradiation of the heart (210). However, the DEX/ANT ratio and dosing interval could have been suboptimal in this study. It has been also demonstrated that DEX pretreatment (20:1) is able to very effectively prevent the onset of both degenerative changes and apoptotic cell death induced by chronic ANT treatment in rabbits (DAU 3 mg/kg, weekly for 10 weeks) (208). DEX treatment rescued cardiomyocytes from complex proapoptotic signaling, and resulting cell death and parameters of apoptosis correlated well with the cardiotoxicity parameters. Surprisingly, effective cardioprotection with DEX was not associated with significant decrease of moderately elevated markers of lipoperoxidation. In addition, no correlation has been found between myocardial malondialdehyde levels and parameters of cardiac function (208).

Using a model of late-onset chronic ANT cardiotoxicity (DOX 0.8 mg/kg, weekly for 7 weeks, and 37-week follow-up), Lebrecht *et al.* have found that DEX can protect the heart mitochondria from late-onset DOX-induced genetic and functional lesions and raise of TBARS. Interestingly, DEX pretreatment markedly reduced the DOX-induced damage to mtDNA (mtDNA/nDNA copy number and occurrence of common deletions) and overcame DOX-induced decline in expression of mtDNA-encoded subunits of the respiratory chain (150). Another study has shown that DEX is able to prevent complex changes in myocardial metabolism induced by chronic DOX treatment (35).

DEX pretreatment (50 mg/kg) has prevented down-regulation of myocardial ryanodine receptor expression induced by chronic DOX treatment (2.5 mg/kg, weekly for 6 weeks) in rats (31). Others have documented that DEX (40 mg/kg) markedly reduces deleterious effects of DOX (2 mg/kg, weekly for 4 weeks) on trabecular actin-myosin crossbridge cycle (45). DEX (60 mg/kg weekly) was also able to prevent an increase in myocardial total calcium content induced by chronic DAU treatment (3 mg/kg, weekly for 10 weeks) (241). Interestingly, in the latter study, the chronic ANT treatment with or without DEX had no impact on total myocardial iron levels.

Cardioprotection against ANT cardiotoxicity in clinical trials

Cardioprotective effects of DEX against ANT-induced cardiotoxicity have been unambiguously demonstrated in numerous clinical trials and in both adults and children (169, 170, 177, 252, 260, 305). Importantly, significant cardioprotection has been achieved in various chemotherapy regimens, using different DEX-to-ANT ratios and all ANTs in clinical use. Cardioprotective potential of DEX has been evaluated by clinical examination (incidence of cardiac events and symptoms of CHF), using cardiac function examinations (echocardiography or radionuclide ventriculography), by analysis of biochemical markers (*e.g.*, plasma concentrations of cardiac troponins) and/or endomyocardial biopsy.

Pioneering randomized controlled trial conducted by Speyer *et al.* has shown that DEX permits breast cancer patients to receive significantly more cycles of chemotherapeutic regimen (9 *vs.* 11, $p < 0.001$) and to achieve higher cumulative

doses of DOX (441 *vs.* 500, $p < 0.01$) with much lower rate of DOX-induced cardiac events (252). Swain *et al.* have revealed that DEX is also effective when launched in patients exceeding a cumulative dose of DOX of 300 mg/m² without prior protection (259). Other studies have confirmed the cardioprotective significance of DEX in mixed cohorts involving both adults and children (171, 290). Importantly, the randomized prospective trial by Lipshultz *et al.* has clearly shown that DEX may prevent cardiotoxicity onset in children with ≈ 2.5 -year follow-up after the chemotherapy (169). A nonrandomized prospective trial by Elbl *et al.* has suggested that DEX affords a long-term cardioprotection from both clinical and subclinical cardiotoxicity in 8-year follow-up after the ANT treatment (57). In addition, a retrospective study in children with a follow-up of 2–20 years (7 years median) suggested a reduction of both clinical and subclinical signs of late-onset cardiotoxicity in children receiving DEX (58). In a recent prospective randomized study, DEX has been demonstrated to provide a long-term cardioprotection (5-year follow-up) in children, and the benefits from DEX treatment seemed to be more significant in girls than in boys (170). Finally, the cardioprotective effectiveness of DEX has been also supported by the recent meta-analysis of all randomized controlled trials of ANT-treated oncologic patients (275).

Question of potential interference with anticancer effect of ANTs

Firstly, the DEX-afforded cardioprotection has been shown to be not due to its impact on ANT pharmacokinetics and metabolism (13, 113, 219). However, as both ANTs and DEX share an important molecular target, TOP2, the question of potential interference of DEX with anticancer effects of these agents is appropriate.

Early preclinical examinations have shown no effect on anticancer effects of DOX (94, 281). Later on, a significant synergism with ANTs has been reported in a leukemia cell line (30), while others have reported the possibility of antagonism on proliferating noncancer Chinese hamster ovary cells (92). The tumor response was also carefully observed during first two stages of clinical evaluation of this drug. No suggestions of significant impairment of anticancer effects of ANTs have been recognized.

Significant, although not well evidenced, suspicion on potential interference of DEX with anticancer effects of ANTs has arisen from one of phase III trials (260). At this stage, two studies with very similar design have been conducted. In the first trial ($n=123$), no difference in any oncological endpoints has been found (objective response rate was 54% and 49%; $p=0.63$ in DEX and placebo-treated group, respectively). However, from another trial ($n=293$), a significant difference in objective response has been reported (47% *vs.* 61%, respectively, $p=0.019$) (260). While unusual was the rather high response in the placebo group, and no other endpoints (including survival or time to progression) were affected in either of these studies, DEX became suspected for negative effect on tumor response. This has been reflected in recommendations for DEX use given by various oncological societies, and DEX has not been recommended for use during initial ANT treatment, but only after the cumulative dose of DOX exceeds 300 mg/m² (95).

The above-described study has been analyzed in depth with conclusion that these data cannot conclusively blame

DEX from reduction of tumor response (257). No significant effect on any oncological parameter has been found ever since, and most importantly, careful meta-analyses of all randomized clinical trials have found no evidence for this hypothesis (235c, 275). However, the stain has remained on DEX, and clinical guidelines as well as oncological practice have not been changed in the light of these data.

Adverse effects

DEX has been reported to be relatively a low-toxic drug, well tolerable by both animals of different species as well as cancer patients (41). Leukopenia and myelotoxicity have been established in early phases of clinical evaluation as the dose-limiting toxicities (283), which are likely due to the TOP2 inhibition induced by the parent DEX molecule. Leukopenia has been also reported as the only grade 3/4 adverse event significantly more frequent in DEX-cotreated cancer patients (260). In addition, less-serious adverse effects included mild-to-moderate increase of risk of anemia, nausea, and fatigue, while phlebitis was more frequent (41). One clinical study has suggested that DEX may increase incidence of secondary hematological malignancies (264), whereas another randomized controlled clinical trial designed and powered for this purpose has found no evidence for these potentially serious adverse effects of DEX (12).

DEX-afforded tissue protection beyond the ANT-induced cardiotoxicity

Besides cardioprotection against ANT-induced cardiac injury, DEX has been reported to protect the kidneys from experimental ANT-induced nephrotoxicity (307, 311). Broader cardioprotective potential has been suggested from experimental studies on ischemia/reperfusion injury (212, 310) and catecholamine-induced cardiotoxicity (63, 93, 205, 306). Although many of these results appeared interesting, the only additional clinical indication for DEX becomes a protection of tissue in accidental ANT extravasation—a rare, but potentially serious, adverse effect associated with long-lasting local damage, ulceration, and necrosis. Langer *et al.* have reported that systemic treatment with DEX (250 mg/kg or triple treatment with 62.5 mg/kg) markedly decreases the area of wound and healing time when started immediately after induction of ANT extravasation in mice (148, 149). However, such effects were not achievable with ADR-925, EDTA, N-acetylcystein, vitamin E, merbarone, or aclarubicin, which does not suggest involvement of iron chelation, oxidative stress, or TOP2 inhibition (149). Conversely, DEX failed to protect the tissues from hydrogen peroxide-induced tissue damage (149). The mechanisms of tissue protective effects of DEX therefore remain undetermined in this setting.

DEX Derivatives As Cardioprotectants

A number of dioxopiperazine derivatives have been studied for their anticancer and TOP2 inhibition effects (40). However, much less information is available regarding their ability to protect the myocardium against ANT-induced damage. An early study performed by Herman *et al.* (98) has evaluated the protective action of 19 bisdioxopiperazines together with DEX (12.5–200 mg/kg) against acute DAU toxicity (25 mg/kg) in Syrian golden hamsters. Only three compounds were found effective in terms of reducing the

mortality rate and body weight loss (DEX, levorazoxane-ICRF-186, and bimolane-AT-1727), whereas a minimal effect was observed in other five compounds. Later on, it has been shown that DEX and its optic isomer levorazoxane have comparable or slightly lower cardioprotective effects on a chronic SHR model (308). Although other bisdioxopiperazine derivatives also yield the iron-chelating hydrolytic products (49, 118), systematic evaluation of DEX derivatives on chronic ANT cardiotoxicity models has not been performed until 1997. Herman *et al.* have evaluated ADR-925 and four bisdioxopiperazine derivatives (50 mg/kg, intraperitoneally) on a well-established SHR model (DOX 1 mg/kg, weekly for 12 weeks), and the results were compared to DEX. None of tested DEX derivatives was superior to DEX in terms of cardioprotection (evaluated by histopathology) and prevention of premature death. The marked cardioprotection and decreased mortality rate were found in a demethylated derivative of DEX (ICRF-154) and bis(N-morpholinomethyl) derivative (ADR-559) (Fig. 7). Significant cardioprotection has been also found in ICRF-197 and ADR-239 (Fig. 7), whereas no protection was found in ADR-925 and an ethyl analog of DEX (ICRF-192). These observations contrasted with the notion that all examined compounds are well hydrolysable to metal-chelating products that can displace the iron from complexes with DOX. Although the authors suggested an alternative link to ability of these agents to inhibit TOP2, it might be noted that generally a higher response was seen in agents with better solubility. Thus, potential difference in absorption and pharmacokinetic profile may complicate interpretation of the structure-activity pharmacodynamic data.

More recently, Martin *et al.* have performed an elegant study in which the effects of DEX were directly compared with those of ICRF-161 (a close bisdioxopiperazine analog of DEX without TOP2 inhibition properties, Fig. 7) (176). Both compounds were found hydrolyzable to iron-chelating products, and they were comparable in their effectiveness to displace iron from its complex with DOX. Although both compounds inhibited release of LDH from neonatal cardiomyocytes incubated with 1.8 μ M DOX, only DEX has been found significantly protective on a well-established chronic

ANT model in SHR (DOX 1 mg/kg, weekly for 12 weeks). Unlike DEX, ICRF-161 was unable to significantly decrease DOX-induced premature death and typical histopathological changes in the myocardium despite very similar pharmacokinetic profile of both drugs. These data strongly suggest that (i) mere iron-chelating activity is not a sufficient predictor of cardioprotective effect; (ii) short-term exposure of cardiomyocytes *in vitro* may not be a reliable predictor of cardioprotective properties of the drug without confirmation on appropriate chronic model, and (iii) it is not sure whether TOP2 effects and effective cardioprotection are dissectible. Hence, further mechanistic studies with focus on structure-activity relationships with employment of DEX-validated chronic ANT models are needed to shed more light on this issue.

Iron Chelators As Cardioprotective Agents

The idea of iron chelation as a means of prevention of the ANT cardiotoxicity arose with the discovery of the cardioprotective effects of DEX. As already mentioned, ADR-925, a DEX hydrolysis product, can chelate free intracellular iron as well as displace Fe^{3+} from its complex with DOX, and these effects have been long accepted as responsible for cardioprotection (87). Furthermore, it has been demonstrated that in iron-overload conditions, the ANT-induced cardiotoxicity is markedly aggravated (166). Taken together, this provided a strong rationale for studies of ANT cardiotoxicity prevention with iron chelators. While the classical antioxidants scavenge the ROS once they had been formed, chelators are able to prevent the formation of highly toxic $\bullet\text{OH}$ through the iron-catalyzed Fenton and Haber-Weiss reactions (68, 84).

An important question regarding any cardioprotective intervention during ANT therapy is whether the prospective cardioprotective drug can decrease the heart damage caused by ANTs without reducing the antitumor efficacy. Despite rare early data, suggesting that DFO might interfere with DOX cytotoxicity in MCF-7 human breast cancer cells (51), it is now generally accepted that iron-mediated ROS formation is not important for anticancer effects of ANTs (297). Nevertheless, different iron chelators, in addition to being examined

FIG. 7. Chemical structures of selected bisdioxopiperazine derivatives tested for their cardioprotective effects against anthracycline cardiotoxicity.

as protectors against ANT-induced cardiotoxicity *in vitro* and/or *in vivo* (see below), have been also shown not to blunt the antiproliferative effects of ANTs in various cancer cell lines (209, 243, 256).

It should be noted that—with the exception of few DEX analogs (108)—no chelator has been specifically designed for

use in prevention of ANT cardiotoxicity. Most of the agents studied so far have been primarily developed and/or used for the management of patients with chronic iron overload, such as those with β -thalassemia major (134). Studies on ANT cardiomyopathy prevention with iron chelators are summarized in Table 1.

TABLE 1. EXPERIMENTAL STUDIES ON VARIOUS IRON CHELATORS AS PROTECTORS AGAINST ANTHRACYCLINE CARDIOTOXICITY

<i>Fe chelator</i>	<i>Study</i>	<i>Model</i>	<i>Protection (+/–)</i>	<i>Methodology</i>
Deferoxamine (DFO)	al Harbi <i>et al.</i> (1992)	Rats <i>in vivo</i> (acute experiment)	+	Serum LDH, GOT, CPK, histology
	Hershko <i>et al.</i> (1993)	Neonatal rat cardiomyocytes <i>in vitro</i>	+ (iron-overloaded cells) – (normal cells)	LDH release, contractile activity
	Herman <i>et al.</i> (1994)	Spont. hypertensive rats <i>in vivo</i> (chronic experiment)	–	Histology
	Voest <i>et al.</i> (1994)	Isolated mouse left atria (acute experiment)	+ (200 μ M) – (500 μ M)	Contractility
	Saad <i>et al.</i> (2001)	Rats <i>in vivo</i> (acute experiment)	+	CK-MB, LDH, AST, GSH, MDA
Deferiprone (L1)	Barnabe <i>et al.</i> (2002)	Neonatal rat cardiomyocytes <i>in vitro</i>	+	LDH release
	Link <i>et al.</i> (1996)	Neonatal rat cardiomyocytes <i>in vitro</i>	+	Mitochondrial function
	Xu <i>et al.</i> (2006)	Isolated rat paired atria (acute experiment)	+	Contractility, mitochondrial ultrastructure
	Popelova <i>et al.</i> (2009)	Rabbits <i>in vivo</i> (chronic experiment)	–	Mortality, functional parameters (LV FS, LV dP/dt _{max} , dP/dt _{min}), histology, biochemistry (cTnT)
	Ammar <i>et al.</i> (2011)	Rats <i>in vivo</i> (acute experiment)	+	ECG, serum CK-MB, LDH, myocardial MDA, GSH
Deferasirox (ICL670A)	Hasinoff <i>et al.</i> (2003)	Neonatal rat cardiomyocytes <i>in vitro</i>	–	LDH release
PIH	Simunek <i>et al.</i> (2005)	Rabbits <i>in vivo</i> (chronic experiment)	+ / – ^a (25 mg/kg i.p.) – (50 mg/kg i.p.)	Mortality, functional parameters (LV EF, LV dP/dt _{max}), histology, biochemistry (cTnT)
<i>o</i> -108	Sterba <i>et al.</i> (2006)	Rabbits <i>in vivo</i> (chronic experiment)	+ (10 mg/kg i.p.) – (25 mg/kg i.p.)	Mortality, functional parameters (LV EF, LV dP/dt _{max}), histology, biochemistry (cTnT)
SIH	Sterba <i>et al.</i> (2007)	Rabbits <i>in vivo</i> (chronic experiment)	+ (1 mg/kg i.v.) – (2.5 mg/kg i.v.)	Mortality, functional parameters (LV EF, LV dP/dt _{max}), histology, biochemistry (cTnT)
	Simunek <i>et al.</i> (2009)	Neonatal rat cardiomyocytes <i>in vitro</i>	+ ^b	LDH release
Dp44mT	Hasinoff <i>et al.</i> (2009)	Neonatal rat cardiomyocytes <i>in vitro</i>	–	LDH release
	Rao <i>et al.</i> (2011)	Spont. hypertensive rats <i>in vivo</i> (chronic experiment)	–	Histology, apoptosis <i>in vivo</i> , biochemistry (cTnT)

^aImproved survival of animals, but cardioprotection did not reach statistical significance.

^bPartial cytoprotection, but no effect on daunorubicin-induced lipid peroxidation.

PIH, pyridoxal isonicotinoyl hydrazone; *o*-108, *ortho*-chlorobenzoyl isonicotinoyl hydrazone; SIH, salicylaldehyde isonicotinoyl hydrazone; Dp44mT, Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone; LDH, lactate dehydrogenase; MDA, malondialdehyde; cTnT, cardiac troponin T; LV EF, left ventricular ejection fraction; GOT, glutamic-oxalacetic transaminase; CPK, creatinine phosphokinase; CK-MB, creatinine kinase (muscle and brain types); AST, aspartate transaminase; GSH, glutathione; ECG, electrocardiography; i.v., intravenously; i.p., intraperitoneally.

FIG. 8. Chemical structures of iron chelators tested for their cardioprotective effects against anthracycline cardiotoxicity.

Deferoxamine (also desferrioxamine [DFO] Fig. 8) is a well-established hexadentate-chelating agent long used to remove excess iron from the body. In iron overload, it acts by binding free iron in the bloodstream and enhancing its elimination in the urine. By removing excessive iron, DFO significantly reduces the damage to various organs and tissues, such as the liver and heart (134). With respect to ANT cardiotoxicity, DFO received the main attention in the early 1990s. It has been shown to protect the isolated rat neonatal cardiomyocytes against DOX, however, only in the iron-overloaded cells. In contrast, the DFO treatment of normal cardiomyocytes had no measurable cardioprotective effect against DOX toxicity, whether DFO was administered before or simultaneously with DOX (111). Using an acute model of DOX-exposed mouse atria, Voest *et al.* (282) showed that at the concentration of 200 μM DFO was the most effective protectant of the six various chelators tested, including the DEX. However, with slight increase of DFO concentration to 500 μM , its protective effects completely disappeared. In another acute cardiotoxicity study, DFO was able to protect the heart against lesions induced by single very high DOX (15 and 25 mg/kg) doses (3, 221). In contrast, using a well-established SHR model of chronic ANT cardiomyopathy, Herman *et al.* (106) have reported a failure of DFO to achieve a meaningful cardioprotection and reduction of DOX-induced death. A conceivable explanation of these findings was a limited penetration of DFO into the cardiomyocytes due to its high molecular weight

and hydrophilicity. While DFO is among the fastest and most efficient iron chelators in solution, its access to intracellular labile iron pool is limited. Furthermore, a short plasma half-life of DFO may also reduce its potential. In fact, numerous previous studies have demonstrated that DFO is clearly inferior in protecting cardiac cells from oxidative stress-inducing agents as compared to smaller and more lipophilic ligands (15, 93, 188, 238), and therefore during the last years, the research interest shifted in this direction.

Deferiprone (L1 and CP 20, Fig. 8) is an orally effective α -ketohydroxypyridine iron chelator, effective both in monotherapy or in combination with DFO (134). In contrast to DFO, L1 is a small lipophilic molecule; it penetrates well into various tissues and is able to remove excess iron from the heart (114). It has been also shown to efficiently bind labile cellular iron, both free as well as accumulated within the mitochondria and lysosomes (74). So far, only a limited number of studies have been examining the antioxidant potential of L1 in iron overload-free conditions. L1 protected neurons as well as fibroblasts against H_2O_2 -induced cell death *in vitro* (165, 189). It also protected an H9c2 cardiomyoblast-derived cell line against model oxidative injury induced by *tert*-butyl hydroperoxide (15) and rat hearts against the ischemia–reperfusion injury (276). Two *in vitro* studies demonstrated that treatment with L1 resulted in an inhibition of DOX (0.6–1.8 μM) toxicity in both iron-loaded and normal cardiac culture cells (10, 166). L1 also protected the spontaneously

beating isolated rat atria against the contractility impairment induced by acute 30 μ M DOX exposure (299). Hence, several lines of evidence indicated that L1, being already a clinically approved drug, might be a promising and readily available option to increase the cardiac safety of cancer patients undergoing treatment with ANTs.

Nevertheless, in a study on a clinically relevant and DEX-validated model of chronic ANT-induced cardiotoxicity in rabbits (239), L1 showed no potential to alleviate either ANT-induced oxidative stress or the LV cardiac damage and CHF, as assessed by both echocardiography and LV catheterization (209). L1 was administered orally in two doses of 10 and 50 mg/kg, 45 min before each DAU injection (3 mg/kg i.v.), and the higher L1 dose (50 mg/kg, well tolerated when administered alone) actually led to earlier animal deaths (209). The doses and timing of L1 administration were specifically designed according to the pharmacokinetic study performed in rabbits (65) to achieve and maintain drug concentrations affording significant protection against ANT cardiotoxicity *in vitro* (10, 65). Of note, in the most recent *in vivo* study, oral 10-day administration of L1 (10 mg/kg daily) protected the rat hearts against acute cardiotoxicity induced by a single high DOX dose (15 mg/kg) (6), which again points on the marked difference between acute and chronic ANT cardiotoxicity.

Deferasirox (ICL670A, Fig. 8) is the newest clinically approved orally active iron chelator. It is a synthetic triazole chelator that has been also shown capable to remove cardiac iron and attenuate myocardial oxidative stress in the state of iron overload (4). It has been shown as capable to protect H9c2 cells from *tert*-butyl hydroperoxide (15), significantly retard the spontaneous catecholamine oxidation, block the intracellular ROS formation, and exert significant protection against the cellular toxicity of catecholamines and their oxidation products with very low (3 μ M) effective concentrations (93). ICL670A, tested in the same *in vitro* model as the L1, did not protect isolated rat cardiomyocytes against DOX (89). Depending upon the concentration, ICL670A either did not affect the DOX toxicity to cardiomyocytes, or even synergistically increased it. Interestingly, this occurred in spite of the fact that ICL670A quickly and efficiently removed Fe^{3+} from its complex with DOX, rapidly entered myocytes, and displaced iron from an intracellular iron–calcein complex. The fact that the ferric complex of ICL670A was less toxic than ICL670A alone suggested that ICL670A was cytotoxic either by removing or by withholding iron from critical iron-containing proteins (89).

Aroylhydrazones are represented by pyridoxal isonicotinoyl hydrazone (PIH, Fig. 8) and its analogs. This class of chelators has been primarily developed as orally active agents for management of iron overload (33). Previously, micromolar concentrations of PIH were shown to protect plasmid DNA from damage by Fe^{2+} and H_2O_2 (110). Salicylaldehyde isonicotinoyl hydrazone (SIH, Fig. 8) was highly effective in the protection of guinea pig-isolated cardiomyocytes, H9c2 cells, as well as other cell types against the H_2O_2 -induced cell injury, apparently due to the preservation of mitochondrial function and/or lysosomal integrity (115, 145, 172, 238). In the *in vivo* conditions, PIH prevented ischemia–reperfusion injury of retina in a neonatal piglet model where it was markedly more effective than DFO (20). To date, the cardioprotective effects against ANT-induced cardiotoxicity of three aroylhydrazone analogs have been evaluated: PIH,

SIH, and *o*-108 (*ortho*-chlorobenzoyl isonicotinoyl hydrazone, Fig. 8). Using a rabbit model of chronic DAU cardiomyopathy, firstly PIH was found to reduce the DAU-induced death (240). SIH and *o*-108 prevented both premature deaths of animals as well as significantly improved the DAU-induced impairment of cardiac function (LV EF, $\text{dP}/\text{dt}_{\text{max}}$), biomarkers of cardiac injury (cTnT), as well as histopathological parameters (255, 256). However, dose escalation of all the aroylhydrazone chelators did not provide additional protection, but on the contrary, it hampered virtually all the beneficial effects of the chelators regarding both overall mortality rate and cardioprotection (244, 255, 256). Importantly, these higher chelators' doses were nontoxic and well tolerated when administered to animals alone. Theoretically, the equivocal results of aroylhydrazone chelators *in vivo* could have pharmacokinetic background. The inability of aroylhydrazone chelators to provide the same degree of protection as DEX could be attributable to their relatively rapid degradation and short plasma half-life, whereas the disappearance of the cardioprotective effect after higher doses might potentially be associated with too high peak plasma concentrations overshooting a desirable degree of iron chelation in ANT-treated cardiomyocytes (140–142). Therefore, in an attempt to shed light on the results of *in vivo* experiments, an *in vitro* study examining protection by SIH against DAU cardiotoxicity and involved mechanisms was conducted, using primary culture of neonatal rat ventricular cardiomyocytes (243). SIH has been shown to protect cardiomyocytes against the 48 h incubation with 10 μ M DAU. However, the protection was only partial and with no apparent dose dependency: the reduction of DAU-induced toxicity by 3 μ M SIH (22%) was comparable with that of 100 μ M SIH (25%; nonsignificant). This sharply contrasted with protection against model oxidative injury by 500 μ M H_2O_2 , where SIH pretreatment resulted in dose-dependent protection with EC_{50} value of 2.1 μ M and complete (100%) protection at SIH concentrations higher than 10 μ M (243). The observed protection with SIH against both DAU and H_2O_2 was dependent on iron chelation, as it could be blunted by increasing the concentration of iron salts in the incubation medium. However, while SIH completely abolished the H_2O_2 -induced significant increase of a lipid peroxidation marker, the protection by SIH against DAU cardiotoxicity was not accompanied by any significant change in this parameter (243).

Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT, Fig. 8) is a thiosemicarbazone anticancer iron chelator (291, 305). Dp44mT has been shown as a very effective agent in intracellular iron chelation, and under certain conditions, it was able to protect the cells against oxidative stress—low concentrations of Dp44mT (1 μ M) were able to significantly protect H9c2 cardiomyoblasts against 200 μ M *tert*-butyl hydroperoxide (15). Even though Dp44mT has shown some tendency to increase ascorbate oxidation under cell-free conditions, it was the most potent agent in reduction of intracellular ROS production (15). However, Dp44mT has failed to reduce DOX cardiotoxicity both *in vitro* (88) and *in vivo* (213). Dp44mT may form redox-active iron or copper complexes (127), and it is therefore possible that the ability of Dp44mT to protect the biomolecules or cells against oxidative injury is concentration-, system-, and/or context-dependent.

To summarize, studies with various iron-specific chelators (both clinically approved drugs as well as experimental

agents) have yielded rather mixed results, particularly when evaluated on clinically relevant animal models of chronic ANT-induced toxicity. Clearly, none of the agents reached the high and experimental model-independent protective efficiency of DEX. This has been observed despite the fact that the studied agents are even stronger and more selective intracellular iron chelators being able to displace iron from its complexes with ANTs, and their own complexes with this metal are less likely to redox cycle than those of ADR-925. Furthermore, in some of those studies, the cardioprotective dose range was quite narrow, and even a slight (≈ 2.5 -fold) dose increase resulted in a disappearance of protective activity (244, 255, 256, 282). It should be noted that while DEX is a prodrug that can be bioactivated to the chelating metabolite ADR-925 at the site of its effect, all the above-listed iron chelators are active ligands from the moment of administration. Of note, aroylhydrazones prochelators have been recently developed where the Fe-binding groups are chemically masked, and the active chelators PIH and SIH are generated only at the sites of ROS production (35b, 35c, 304). Unfortunately, to date, none of these agents has been tested so far as a protector against ANT cardiotoxicity. In addition, unlike the chelators discussed above, ADR-925 is far from being selective for iron, and thus it cannot be excluded that chelation of other biometals can be involved in the DEX action.

More recently, it has been shown that ANTs are able to interact with cellular iron in a more complex way than merely producing the toxic free oxygen radicals (Fig. 9). *In vitro*, ANTs decreased the binding of IRPs to the iron-responsive elements of mRNA, thus modifying expression of the proteins

that are critical for maintaining optimal intracellular iron levels (186). Kwok and Richardson have shown that DOX induced an accumulation of iron in ferritin and prevented its mobilization, which might possibly result in functional iron deficit (147). Therefore, iron chelators might also interfere with ANTs and cellular iron in a more complex way than only shielding free iron from being a catalyst in Fenton chemistry. It is possible that an excessive iron binding, such as that apparently induced with ICL670A or Dp44mT treatments (88, 89) and too high doses of DFO (282) or aroylhydrazones (244) might exceed the optimal degree of chelation and rather act synergically with the ANT-induced iron metabolism misbalance. Of note, oxidative stress may not be only caused by iron excess, but oxidant-induced damage to mitochondria has been also described from iron deficiency (287). In fact, there is also considerable uncertainty regarding possible spatiotemporal requirement of metal chelation in ANT cardiotoxicity settings.

Apart from (relatively) selective chelators of iron, limited attention has been paid to chelators of other metals. Sodium 2,3-dimercaptopropane-1-sulfonate (DMPS) is a dithiol orally active chelating agent that may be used for treatment of poisoning with heavy metals such as mercury or arsenic (130). Tested on the rabbit model of chronic DAU-induced cardiotoxicity, DMPS has not shown any protective effects (117). Interestingly, no study has been published so far with copper chelators, such as *D*-penicillamine. Given the propensity of copper to catalyze the Fenton reaction, which is even higher than that of iron (84), and in the light of the still-prevailing oxidative stress hypothesis of ANT-induced cardiotoxicity, this approach warrants investigation.

FIG. 9. Schematic illustration of anthracycline-induced changes in iron metabolism. DMT1, divalent metal transporter 1; FPN, ferroportin 1; Mfrn, mitoferrin; MtF, mitochondrial ferritin; STEAP, six-transmembrane epithelial antigen of prostate 3; Tf, transferrin; TfR, transferrin receptor. (To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars.)

Concluding Remarks

ANTs continue to play an undisputed role in the treatment of many forms of cancer, including hematological malignancies and solid tumors. Their clinical use has resulted in prolongation of lifespan of cancer patients, but also it has brought the risk of cardiotoxicity, which negatively affects the long-term outcomes. Considerable body of evidence demonstrated that DEX markedly reduces or even prevents ANT-induced cardiotoxicity in the clinical settings. However, due to its real or assumed drawbacks, DEX is unfortunately underutilized, which creates a room for alternative cardioprotective agents.

The classical ROS and iron hypothesis of ANT-induced cardiotoxicity is listed on the first place in practically all textbooks and a vast majority of review articles. Indeed, the DEX-afforded effective cardioprotection has been the strongest piece of evidence supporting this theory. However, studies with other iron-chelating agents—often stronger, more selective for iron, and less redox active than ADR-925—have yielded no or only partial response. Furthermore, some recent data cast doubts on the real role of DEX metabolites in the cardioprotective effects seen after DEX administration, and a detailed PK/PD approach focused on the heart may shed more light on this issue. Furthermore, if the metal chelation is indeed involved, its intracellular spatiotemporal characteristic might be critical. In recent years, numerous alternative or complementary theories have been proposed and described for both ANT cardiotoxicity and protection. The critical problem is enormous heterogeneity of the experimental models used and little effort on confirmation of proposed hypotheses using long-term chronic animal models. This may explain many contradictory findings and questionable translatability of some experimental data into the real-world clinical situation. Hence, although huge amounts of data have been published, it is very difficult to arrange them to a clear and cohesive picture. Therefore, continued efforts need to be placed on further research of the molecular pathogenesis of ANT cardiotoxicity as well as search for alternative cardioprotective therapies.

Acknowledgments

The authors' own work has been supported by the Czech Science Foundation (grant GACR 305/09/0416), the Internal Grant Agency of the Ministry of Health of the Czech Republic (grant NT13457-4/2012), and the Charles University in Prague (grants UNCE 33/2012 and SVV 265004, the program PRVOUK P37/5).

References

- Adachi K, Fujiura Y, Mayumi F, Nozuhara A, Sugiu Y, Sakanashi T, Hidaka T, and Toshima H. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. *Biochem Biophys Res Commun* 195: 945–951, 1993.
- Adams MJ and Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. *Pediatr Blood Cancer* 44: 600–606, 2005.
- al-Harbi MM, al-Gharably NM, al-Shabanah OA, al-Bekairi AM, Osman AM, and Tawfik HN. Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. *Cancer Chemother Pharmacol* 31: 200–204, 1992.
- Al-Rousan RM, Paturi S, Laurino JP, Kakarla SK, Gutta AK, Walker EM, and Blough ER. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. *Am J Hematol* 84: 565–570, 2009.
- Alderton P, Gross J, and Green MD. Role of (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. *Cancer Res* 50: 5136–5142, 1990.
- Ammar el SM, Said SA, Suddek GM, and El-Damarawy SL. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. *Can J Physiol Pharmacol* 89: 269–276, 2011.
- Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, and Spalla C. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from *S. peucetius* var. *caesius*. *Biotechnol Bioeng* 11: 1101–1110, 1969.
- Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, and Voipio-Pulkki LM. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. *Cancer Res* 60: 1789–1792, 2000.
- Bachur NR, Gordon SL, and Gee MV. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. *Mol Pharmacol* 13: 901–910, 1977.
- Barnabe N, Zastre JA, Venkataram S, and Hasinoff BB. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. *Free Radic Biol Med* 33: 266–275, 2002.
- Barry E, Alvarez JA, Scully RE, Miller TL, and Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. *Expert Opin Pharmacother* 8: 1039–1058, 2007.
- Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, and Silverman LB. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. *J Clin Oncol* 26: 1106–1111, 2008.
- Basser RL, Sobol MM, Duggan G, Cebon J, Rosenthal MA, Mihaly G, and Green MD. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. *J Clin Oncol* 12: 1659–1666, 1994.
- Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Guthrie J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, and Lee LW. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. *J Clin Oncol* 19: 1444–1454, 2001.
- Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR, and Simunek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. *Chem Res Toxicol* 23: 1105–1114, 2010.
- Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. *Blood* 77: 1666–1674, 1991.
- Berthiaume JM, Oliveira PJ, Fariss MW, and Wallace KB. Dietary vitamin E decreases doxorubicin-induced oxidative

- stress without preventing mitochondrial dysfunction. *Cardiovasc Toxicol* 5: 257–267, 2005.
18. Berthiaume JM and Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. *Cell Biol Toxicol* 23: 15–25, 2007.
 19. Berthiaume JM and Wallace KB. Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment. *Cardiovasc Toxicol* 7: 178–191, 2007.
 20. Bhattacharya M, Ponka P, Hardy P, Hanna N, Varma DR, Lachapelle P, and Chemtob S. Prevention of postasphyxia electroretinal dysfunction with a pyridoxal hydrazone. *Free Radic Biol Med* 22: 11–16, 1997.
 21. Billingham ME, Mason JW, Bristow MR, and Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. *Cancer Treat Rep* 62: 865–872, 1978.
 22. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, and Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). *Cancer Res* 30: 2572–2582, 1970.
 23. Bonfante V, Bonadonna G, Villani F, and Martini A. Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia. *Recent Results Cancer Res* 74: 192–199, 1980.
 24. Bonfante V, Ferrari L, Villani F, and Bonadonna G. Phase I study of 4-demethoxydaunorubicin. *Invest New Drugs* 1: 161–168, 1983.
 25. Boucek RJ, Jr., Miracle A, Anderson M, Engelman R, Atkinson J, and Dodd DA. Persistent effects of doxorubicin on cardiac gene expression. *J Mol Cell Cardiol* 31: 1435–1446, 1999.
 26. Breed JG, Zimmerman AN, Dormans JA, and Pinedo HM. Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit. *Cancer Res* 40: 2033–2038, 1980.
 27. Bristow MR, Billingham ME, Mason JW, and Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. *Cancer Treat Rep* 62: 873–879, 1978.
 28. Bruynzeel AM, Niessen HW, Bronzwaer JG, van der Hoeven JJ, Berkhof J, Bast A, van der Vijgh WJ, and van Groenigen CJ. The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. *Br J Cancer* 97: 1084–1089, 2007.
 29. Bruynzeel AM, Vormer-Bonne S, Bast A, Niessen HW, and van der Vijgh WJ. Long-term effects of 7-mono-hydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice. *Cancer Chemother Pharmacol* 60: 509–514, 2007.
 30. Budman DR, Calabro A, and Kreis W. *In vitro* effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? *Leukemia* 15: 1517–1520, 2001.
 31. Burke BE, Gambliel H, Olson RD, Bauer FK, and Cusack BJ. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. *Br J Pharmacol* 131: 1–4, 2000.
 32. Buss JL and Hasinoff BB. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). *Arch Biochem Biophys* 317: 121–127, 1995.
 33. Buss JL, Hermes-Lima M, and Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues. *Adv Exp Med Biol* 509: 205–229, 2002.
 34. Capranico G and Zunino F. DNA topoisomerase-trapping antitumour drugs. *Eur J Cancer* 28A: 2055–2060, 1992.
 35. Carvalho RA, Sousa RP, Cadete VJ, Lopaschuk GD, Palmeira CM, Bjork JA, and Wallace KB. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. *Toxicology* 270: 92–98, 2010.
 - 35a. Chaiswing L, Cole MP, Ittarat W, Szweda LI, St Clair DK, and Oberley TD. Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute adriamycin-induced mitochondrial toxicity. *Mol Cancer Ther* 4: 1056–1064, 2005.
 - 35b. Charkoudian LK, Dentchev T, Lukinova N, Wolkow N, Dunaief JL, and Franz KJ. Iron chelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. *J Inorg Biochem* 102: 2130–2135, 2008.
 - 35c. Charkoudian LK, Pham DM, and Franz KJ. A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. *J Am Chem Soc* 128: 12424–12425, 2006.
 - 35d. Chen B, Peng X, Pentassuglia L, Lim CC, and Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. *Cardiovasc Toxicol* 7: 114–121, 2007.
 36. Classen S, Olland S, and Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. *Proc Natl Acad Sci U S A* 100: 10629–10634, 2003.
 37. Cole MP, Chaiswing L, Oberley TD, Edelmann SE, Piascik MT, Lin SM, Kinningham KK, and St Clair DK. The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity. *Cardiovasc Res* 69: 186–197, 2006.
 38. Creaven PJ, Allen LM, and Alford DA. The bioavailability in man of ICRF-159 a new oral antineoplastic agent. *J Pharm Pharmacol* 27: 914–918, 1975.
 39. Creighton AM and Birnie GD. The effect of bisdioxopiperazines on the synthesis of deoxyribonucleic acid, ribonucleic acid and protein in growing mouse-embryo fibroblasts. *Biochem J* 114: 58, 1969.
 40. Creighton AM, Hellmann K, and Whitecross S. Antitumour activity in a series of bisdiketopiperazines. *Nature* 222: 384–385, 1969.
 41. Cvetkovic RS and Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. *Drugs* 65: 1005–1024, 2005.
 42. D'Alessandro N, Candiloro V, Crescimanno M, Flandina C, Dusonchet L, Crosta L, and Rausa L. Effects of multiple doxorubicin doses on mouse cardiac and hepatic catalase. *Pharmacol Res Commun* 16: 145–151, 1984.
 43. Davies KJ and Doroshov JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. *J Biol Chem* 261: 3060–3067, 1986.
 44. Davies KJ, Doroshov JH, and Hochstein P. Mitochondrial NADH dehydrogenase-catalyzed oxygen radical production by adriamycin, and the relative inactivity of 5-iminodaunorubicin. *FEBS Lett* 153: 227–230, 1983.
 45. de Beer EL, Bottone AE, van Rijk MC, van der Velden J, and Voest EE. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics. *Br J Pharmacol* 135: 1707–1714, 2002.
 46. Della Torre P, Mazue G, Podesta A, Moneta D, Sammartini U, and Imondi AR. Protection against doxorubicin-induced

- cardiotoxicity in weanling rats by dexrazoxane. *Cancer Chemother Pharmacol* 43: 151–156, 1999.
47. Deng S, Kruger A, Schmidt A, Metzger A, Yan T, Godtel-Armbrust U, Hasenfuss G, Brunner F, and Wojnowski L. Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. *Naunyn Schmiedebergs Arch Pharmacol* 380: 25–34, 2009.
 48. Deng S and Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. *Cardiovasc Toxicol* 7: 129–134, 2007.
 49. Diop NK, Vitellaro LK, Arnold P, Shang M, and Marusak RA. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. *J Inorg Biochem* 78: 209–216, 2000.
 50. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. *Cancer Res* 43: 460–472, 1983.
 51. Doroshow JH. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. *Biochem Biophys Res Commun* 135: 330–335, 1986.
 52. Doroshow JH and Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. *J Biol Chem* 261: 3068–3074, 1986.
 53. Doroshow JH, Locker GY, and Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. *J Clin Invest* 65: 128–135, 1980.
 54. Dresdale AR, Barr LH, Bonow RO, Mathisen DJ, Myers CE, Schwartz DE, d'Angelo T, and Rosenberg SA. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. *Am J Clin Oncol* 5: 657–663, 1982.
 55. Earhart RH, Tutsch KD, Koeller JM, Rodriguez R, Robins HI, Vogel CL, Davis HL, and Tormey DC. Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. *Cancer Res* 42: 5255–5261, 1982.
 56. El-Demerdash E, Ali AA, Sayed-Ahmed MM, and Osman AM. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity. *Cancer Chemother Pharmacol* 52: 411–416, 2003.
 57. Elbl L, Hrstkova H, Tomaskova I, Blazek B, and Michalek J. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. *Eur J Pediatr* 164: 678–684, 2005.
 58. Elbl L, Hrstkova H, Tomaskova I, and Michalek J. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. *Support Care Cancer* 14: 128–136, 2006.
 59. Ewer MS and Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. *Nat Rev Cardiol* 7: 564–575, 2010.
 60. Ewer MS and Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. *J Clin Oncol* 23: 2900–2902, 2005.
 61. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, and Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 342: 1077–1084, 2000.
 62. Ferrans VJ, Clark JR, Zhang J, Yu ZX, and Herman EH. Pathogenesis and prevention of doxorubicin cardiomyopathy. *Tsitologia* 39: 928–937, 1997.
 63. Flandina C, Sanguedolce R, Rausa L, and D'Alessandro N. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. *Res Commun Chem Pathol Pharmacol* 70: 259–272, 1990.
 64. Fogli S, Nieri P, and Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. *FASEB J* 18: 664–675, 2004.
 65. Fredenburg AM, Wedlund PJ, Skinner TL, Damani LA, Hider RC, and Yokel RA. Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. *Drug Metab Dispos* 21: 255–258, 1993.
 66. Fujita K, Shinpo K, Yamada K, Sato T, Niimi H, Shamoto M, Nagatsu T, Takeuchi T, and Umezawa H. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. *Cancer Res* 42: 309–316, 1982.
 67. Fulbright JM, Huh W, Anderson P, and Chandra J. Can anthracycline therapy for pediatric malignancies be less cardiotoxic? *Curr Oncol Rep* 12: 411–419, 2010.
 68. Galey JB. Potential use of iron chelators against oxidative damage. *Adv Pharmacol* 38: 167–203, 1997.
 69. Gao J, Xiong Y, Ho YS, Liu X, Chua CC, Xu X, Wang H, Hamdy R, and Chua BH. Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. *Biochim Biophys Acta* 1783: 2020–2029, 2008.
 70. Geisberg CA and Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. *Curr Hypertens Rep* 12: 404–410, 2010.
 71. Gersl V and Hrdina R. Noninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits. *Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove* 37: 49–55, 1994.
 72. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, and Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. *J Clin Oncol* 26: 3777–3784, 2008.
 73. Gianni L, Salvatorelli E, and Minotti G. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. *Cardiovasc Toxicol* 7: 67–71, 2007.
 74. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Herskho C, Nick H, and Cabantchik ZI. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. *Blood* 108: 3195–3203, 2006.
 75. Goodman LS, Brunton LL, Chabner B, and Knollmann BC. *Goodman & Gilman's Pharmacological Basis of Therapeutics*. New York: McGraw-Hill, 2010.
 76. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, and Lipshultz SE. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. *J Pediatr* 116: 144–147, 1990.
 77. Goormaghtigh E, Huart P, Praet M, Brasseur R, and Ruyschaert JM. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. *Biophys Chem* 35: 247–257, 1990.
 78. Gosalvez M, Blanco M, Hunter J, Miko M, and Chance B. Effects of anticancer agents on the respiration of isolated mitochondria and tumor cells. *Eur J Cancer* 10: 567–574, 1974.
 79. Gratia S, Kay L, Michelland S, Seve M, Schlattner U, and Tokarska-Schlattner M. Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity. *J Proteomics* 75: 4705–4716, 2012.

80. Greenberg RE, Bahnson RR, Wood D, Childs SJ, Bellingham C, Edson M, Bamberger MH, Steinberg GD, Israel M, Sweatman T, Giantonio B, and O'Dwyer PJ. Initial report on intravesical administration of N-trifluoroacetyl Adriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. *Urology* 49: 471–475, 1997.
81. Gustafson DL, Swanson JD, and Pritsos CA. Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy. *Free Radic Res Commun* 19: 111–120, 1993.
82. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, and Sehoul J. Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. *Support Care Cancer* 16: 267–273, 2008.
83. Hale JP and Lewis IJ. Anthracyclines: cardiotoxicity and its prevention. *Arch Dis Child* 71: 457–462, 1994.
84. Halliwell B and Gutteridge JMC. *Free Radicals in Biology and Medicine*. Oxford; New York: Oxford University Press, 2007.
85. Hasinoff BB. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. *J Pharm Sci* 83: 64–67, 1994.
86. Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. *Cardiovasc Toxicol* 2: 111–118, 2002.
87. Hasinoff BB, Hellmann K, Herman EH, and Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. *Curr Med Chem* 5: 1–28, 1998.
88. Hasinoff BB and Patel D. The iron chelator Dp44mT does not protect myocytes against doxorubicin. *J Inorg Biochem* 103: 1093–1101, 2009.
89. Hasinoff BB, Patel D, and Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. *Free Radic Biol Med* 35: 1469–1479, 2003.
90. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, and Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. *Cardiovasc Toxicol* 3: 89–99, 2003.
91. Hasinoff BB, Schroeder PE, and Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. *Mol Pharmacol* 64: 670–678, 2003.
92. Hasinoff BB, Yalowich JC, Ling Y, and Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. *Anticancer Drugs* 7: 558–567, 1996.
93. Haskova P, Koubkova L, Vavrova A, Mackova E, Hruskova K, Kovarikova P, Vavrova K, and Simunek T. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. *Toxicology* 289: 122–131, 2011.
94. Hellmann K and Rhomberg W. *Razoxane and Dexrazoxane—Two Multifunctional Agents*. Dordrecht: Springer Netherlands, 2010, p. 167–213.
95. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradyshar WJ, Mitchell RB, Thigpen JT, Trotti A, 3rd, von Hoff D, and Schuchter LM. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. *J Clin Oncol* 27: 127–145, 2009.
96. Heon S, Bernier M, Servant N, Dostanic S, Wang C, Kirby GM, Alpert L, and Chalifour LE. Dexrazoxane does not protect against doxorubicin-induced damage in young rats. *Am J Physiol Heart Circ Physiol* 285: H499–H506, 2003.
97. Herman E, Ardalan B, Bier C, Waravdekar V, and Krop S. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. *Cancer Treat Rep* 63: 89–92, 1979.
98. Herman EH, el-Hage AN, Creighton AM, Witak DT, and Ferrans VJ. Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters. *Res Commun Chem Pathol Pharmacol* 48: 39–55, 1985.
99. Herman EH and Ferrans VJ. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. *Cancer Chemother Pharmacol* 16: 102–106, 1986.
100. Herman EH and Ferrans VJ. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. *Cancer Chemother Pharmacol* 32: 445–449, 1993.
101. Herman EH and Ferrans VJ. Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. *Semin Oncol* 25: 15–21, 1998.
102. Herman EH, Ferrans VJ, Myers CE, and Van Vleet JF. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. *Cancer Res* 45: 276–281, 1985.
103. Herman EH, Ferrans VJ, Young RS, and Hamlin RL. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. *Cancer Res* 48: 6918–6925, 1988.
104. Herman EH, Mhatre RM, and Chadwick DP. Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943). *Toxicol Appl Pharmacol* 27: 517–526, 1974.
105. Herman EH, Mhatre RM, Lee IP, and Waravdekar VS. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. *Proc Soc Exp Biol Med* 140: 234–239, 1972.
106. Herman EH, Zhang J, and Ferrans VJ. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. *Cancer Chemother Pharmacol* 35: 93–100, 1994.
107. Herman EH, Zhang J, Chadwick DP, and Ferrans VJ. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. *Cancer Chemother Pharmacol* 45: 329–334, 2000.
108. Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR, Jr., and Ferrans VJ. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. *Cancer Chemother Pharmacol* 40: 400–408, 1997.
109. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, Knapton A, Chai J, and Ferrans VJ. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. *Cancer Chemother Pharmacol* 48: 297–304, 2001.
110. Hermes-Lima M, Nagy E, Ponka P, and Schulman HM. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against $\cdot\text{OH}$ -mediated strand breaks. *Free Radic Biol Med* 25: 875–880, 1998.

111. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, and Pinson A. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. *J Lab Clin Med* 122: 245–251, 1993.
112. Hershko C, Link G, Tzahor M, and Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. *Leuk Lymphoma* 11: 207–214, 1993.
113. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, and Speyer JL. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. *J Natl Cancer Inst* 84: 1725–1730, 1992.
114. Hoffbrand AV, Cohen A, and Hershko C. Role of deferoxamine in chelation therapy for transfusional iron overload. *Blood* 102: 17–24, 2003.
115. Horackova M, Ponka P, and Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H₂O₂ injury in adult cardiomyocytes. *Cardiovasc Res* 47: 529–536, 2000.
116. Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, and Adamcova M. Anthracycline-induced cardiotoxicity. *Acta Medica (Hradec Kralove)* 43: 75–82, 2000.
117. Hrdina R, Gersl V, Klimtova I, Simunek T, Mazurova Y, Machackova J, and Adamcova M. Effect of sodium 2,3-dimercaptopropane-1-sulphonate (DMPS) on chronic daunorubicin toxicity in rabbits: comparison with dexrazoxane. *Acta Medica (Hradec Kralove)* 45: 99–105, 2002.
118. Huang ZX, May PM, Quinlan KM, Williams DR, and Creighton AM. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192. *Agents Actions* 12: 536–542, 1982.
119. Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, Cox C, Phipps S, Pompeu R, and Rosenthal D. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. *J Clin Oncol* 25: 3635–3643, 2007.
120. This reference has been deleted.
121. This reference has been deleted.
122. This reference has been deleted.
123. This reference has been deleted.
124. Imondi AR. Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects. *Semin Oncol* 25: 22–30, 1998.
125. Imondi AR, Della Torre P, Mazue G, Sullivan TM, Robbins TL, Hagerman LM, Podesta A, and Pinciroli G. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. *Cancer Res* 56: 4200–4204, 1996.
126. Jahnukainen K, Jahnukainen T, Salmi TT, Svechnikov K, Eksborg S, and Soder O. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. *Cancer Res* 61: 6423–6427, 2001.
127. Jansson PJ, Hawkins CL, Lovejoy DB, and Richardson DR. The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study. *J Inorg Biochem* 104: 1224–1228, 2010.
128. Javadov S, Hunter JC, Barreto-Torres G, and Parodi-Rullan R. Targeting the mitochondrial permeability transition: cardiac ischemia-reperfusion versus carcinogenesis. *Cell Physiol Biochem* 27: 179–190, 2011.
129. Jensen BV, Skovsgaard T, and Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. *Ann Oncol* 13: 699–709, 2002.
130. Jones MM and Basinger MA. A hypothesis for the selection of chelate antidotes for toxic metals. *Med Hypotheses* 9: 445–453, 1982.
131. Jones RL, Swanton C, and Ewer MS. Anthracycline cardiotoxicity. *Expert Opin Drug Saf* 5: 791–809, 2006.
132. Junjing Z, Yan Z, and Baolu Z. Scavenging effects of dexrazoxane on free radicals. *J Clin Biochem Nutr* 47: 238–245, 2010.
133. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, and Ergin A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. *J Am Coll Cardiol* 48: 2258–2262, 2006.
134. Kalinowski DS and Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. *Pharmacol Rev* 57: 547–583, 2005.
135. Kang YJ, Chen Y, and Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. *J Biol Chem* 271: 12610–12616, 1996.
136. Kang YJ, Zhou ZX, Wang GW, Buridi A, and Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. *J Biol Chem* 275: 13690–13698, 2000.
137. Keizer HG, Pinedo HM, Schuurhuis GJ, and Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. *Pharmacol Ther* 47: 219–231, 1990.
138. Kim DS, Kim HR, Woo ER, Hong ST, Chae HJ, and Chae SW. Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. *Biochem Pharmacol* 70: 1066–1078, 2005.
139. Klimtova I, Simunek T, Mazurova Y, Hrdina R, Gersl V, and Adamcova M. Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. *Hum Exp Toxicol* 21: 649–657, 2002.
140. Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, and Ponka P. HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. *J Chromatogr B Analyt Technol Biomed Life Sci* 838: 107–112, 2006.
141. Kovarikova P, Klimes J, Sterba M, Popelova O, Mokry M, Gersl V, and Ponka P. Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an *in vivo* study. *J Sep Sci* 28: 1300–1306, 2005.
142. Kovarikova P, Mrkvickova Z, and Klimes J. Investigation of the stability of aromatic hydrazones in plasma and related biological material. *J Pharm Biomed Anal* 47: 360–370, 2008.
143. Kozluca O, Olcay E, Surucu S, Guran Z, Kulaksiz T, and Uskent N. Prevention of doxorubicin induced cardiotoxicity by catechin. *Cancer Lett* 99: 1–6, 1996.
144. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, and Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. *J Clin Oncol* 15: 1544–1552, 1997.
145. Kurz T, Gustafsson B, and Brunk UT. Intralysosomal iron chelation protects against oxidative stress-induced cellular damage. *FEBS J* 273: 3106–3117, 2006.
146. Kwok JC and Richardson DR. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines

- decrease RNA-binding activity. *Mol Pharmacol* 62: 888–900, 2002.
147. Kwok JC and Richardson DR. Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. *Mol Pharmacol* 63: 849–861, 2003.
 148. Langer SW, Sehested M, and Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. *Clin Cancer Res* 6: 3680–3686, 2000.
 149. Langer SW, Sehested M, and Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. *Ann Oncol* 12: 405–410, 2001.
 150. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, and Walker UA. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. *Br J Pharmacol* 151: 771–778, 2007.
 151. Lebrecht D, Kirschner J, Geist A, Haberstroh J, and Walker UA. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy. *Cardiovasc Pathol* 19: e167–e174, 2010.
 152. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, and Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. *J Pathol* 207: 436–444, 2005.
 153. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, and Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. *Circulation* 108: 2423–2429, 2003.
 154. Lebrecht D, Setzer B, Rohrbach R, and Walker UA. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. *Nephrol Dial Transplant* 19: 329–336, 2004.
 155. Lebrecht D and Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity. *Cardiovasc Toxicol* 7: 108–113, 2007.
 156. Lefrak EA, Pitha J, Rosenheim S, and Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer* 32: 302–314, 1973.
 157. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, and Freireich EJ. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. *Ann Intern Med* 96: 133–139, 1982.
 158. Legha SS, Wang YM, Mackay B, Ewer M, Hortobagyi GN, Benjamin RS, and Ali MK. Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. *Ann N Y Acad Sci* 393: 411–418, 1982.
 159. Lenihan DJ. Diagnosis and management of heart failure in cancer patient. In: *Cancer and the Heart*, edited by Ewer MS and Yeh E. Hamilton: BC Decker, 2006, pp. 129–138.
 160. Leonard RC, Williams S, Tulpule A, Levine AM, and Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). *Breast* 18: 218–224, 2009.
 161. Levitt GA, Dorup I, Sorensen K, and Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity? *Br J Haematol* 124: 463–468, 2004.
 162. Li T, Danelisen I, Bello-Klein A, and Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. *Cardiovasc Res* 46: 523–530, 2000.
 163. Li T and Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. *Circulation* 102: 2105–2110, 2000.
 164. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, and Sawyer DB. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. *J Biol Chem* 279: 8290–8299, 2004.
 165. Lim CK, Kalinowski DS, and Richardson DR. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. *Mol Pharmacol* 74: 225–235, 2008.
 166. Link G, Tirosh R, Pinson A, and Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. *J Lab Clin Med* 127: 272–278, 1996.
 167. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, and Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. *N Engl J Med* 324: 808–815, 1991.
 168. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, and Colan SD. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. *J Clin Oncol* 20: 1677–1682, 2002.
 169. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, and Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. *N Engl J Med* 351: 145–153, 2004.
 170. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberger DS, Orav EJ, and Colan SD. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. *Lancet Oncol* 11: 950–961, 2010.
 171. Lopez M, Vici P, Di Lauro K, Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D, and Maini CL. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. *J Clin Oncol* 16: 86–92, 1998.
 172. Lukinova N, Iacovelli J, Dentchev T, Wolkow N, Hunter A, Amado D, Ying GS, Sparrow JR, and Dunaief JL. Iron chelation protects the retinal pigment epithelial cell line ARPE-19 against cell death triggered by diverse stimuli. *Invest Ophthalmol Vis Sci* 50: 1440–1447, 2009.
 173. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, and Liu LF. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. *Cancer Res* 67: 8839–8846, 2007.
 174. Mackay B, Ewer MS, Carrasco CH, and Benjamin RS. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. *Ultrastruct Pathol* 18: 203–211, 1994.
 175. Marcillat O, Zhang Y, and Davies KJ. Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. *Biochem J* 259: 181–189, 1989.
 176. Martin E, Thougard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjornelund J, Sehested M, and Jensen LH. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. *Toxicology* 255: 72–79, 2009.

177. Marty M, Espie M, Llombart A, Monnier A, Rapoport BL, and Stahalova V. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. *Ann Oncol* 17: 614–622, 2006.
178. Maslov MY, Chacko VP, Hirsch GA, Akki A, Leppo MK, Steenbergen C, and Weiss RG. Reduced *in vivo* high-energy phosphates precede adriamycin-induced cardiac dysfunction. *Am J Physiol Heart Circ Physiol* 299: H332–H337, 2010.
179. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, and Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. *Life Sci* 65: 1265–1274, 1999.
180. Mavinkurve-Groothuis AM, Kapusta L, Nir A, and Groot-Loonen J. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. *Pediatr Hematol Oncol* 25: 655–664, 2008.
181. Mcfalls EO, Paulson DJ, Gilbert EF, and Shug AL. Carnitine Protection against Adriamycin-Induced Cardiomyopathy in Rats. *Life Sci* 38: 497–505, 1986.
182. Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, and Minotti G. Anthracycline cardiotoxicity. *Expert Opin Drug Saf* 11 Suppl 1: S21–S36, 2012.
183. Menna P, Recalcatti S, Cairo G, and Minotti G. An introduction to the metabolic determinants of anthracycline cardiotoxicity. *Cardiovasc Toxicol* 7: 80–85, 2007.
184. Menna P, Salvatorelli E, and Minotti G. Cardiotoxicity of antitumor drugs. *Chem Res Toxicol* 21: 978–989, 2008.
185. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev* 56: 185–229, 2004.
186. Minotti G, Ronchi R, Salvatorelli E, Menna P, and Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. *Cancer Res* 61: 8422–8428, 2001.
187. Miranda CJ, Makui H, Soares RJ, Bilodeau M, Mui J, Vali H, Bertrand R, Andrews NC, and Santos MM. Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin. *Blood* 102: 2574–2580, 2003.
188. Mladenka P, Kalinowski DS, Haskova P, Bobrovova Z, Hrdina R, Simunek T, Nachtigal P, Semecky V, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Jansson PJ, and Richardson DR. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. *Chem Res Toxicol* 22: 208–217, 2009.
189. Molina-Holgado F, Gaeta A, Francis PT, Williams RJ, and Hider RC. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. *J Neurochem* 105: 2466–2476, 2008.
190. Muindi JR, Sinha BK, Gianni L, and Myers CE. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. *FEBS Lett* 172: 226–230, 1984.
191. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, Szabo C, and Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death *in vivo* and *in vitro*. *Am J Physiol Heart Circ Physiol* 296: H1466–H1483, 2009.
192. Murphy MP. How mitochondria produce reactive oxygen species. *Biochem J* 417: 1–13, 2009.
193. Myers C, Bonow R, Palmeri S, Jenkins J, Corden B, Locker G, Doroshow J, and Epstein S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. *Semin Oncol* 10: 53–55, 1983.
194. Myers CE, Gianni L, Simone CB, Klecker R, and Greene R. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. *Biochemistry* 21: 1707–1712, 1982.
195. Myers CE, McGuire W, and Young R. Adriamycin: amelioration of toxicity by alpha-tocopherol. *Cancer Treat Rep* 60: 961–962, 1976.
196. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, and Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: *in vivo* study. *Circulation* 102: 572–578, 2000.
197. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, and Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol* 15: 440–449, 2004.
198. O'Brien TA, Russell SJ, Vowels MR, Oswald CM, Tiedemann K, Shaw PJ, Lockwood L, Teague L, Rice M, and Marshall GM. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. *Blood* 100: 2708–2716, 2002.
199. Ohkura K, Lee JD, Shimizu H, Nakano A, Uzui H, Horikoshi M, Fujibayashi Y, Yonekura Y, and Ueda T. Mitochondrial complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat. *Mol Cell Biochem* 248: 203–208, 2003.
200. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, and Wallace KB. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. *Toxicol Appl Pharmacol* 200: 159–168, 2004.
201. Oliveira PJ and Wallace KB. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats—relevance for mitochondrial dysfunction. *Toxicology* 220: 160–168, 2006.
202. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT, and Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. *Circulation* 107: 896–904, 2003.
203. Pan SS and Bachur NR. Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation. *Mol Pharmacol* 17: 95–99, 1980.
204. Panjath GS, Patel V, Valdiviezo CI, Narula N, Narula J, and Jain D. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. *J Am Coll Cardiol* 49: 2457–2464, 2007.
205. Persoon-Rotherth M, van der Valk-Kokshoorn EJ, Egas-Kenniphaas JM, Mauve I, and van der Laarse A. Isoproterenol-induced cytotoxicity in neonatal rat heart cell cultures is mediated by free radical formation. *J Mol Cell Cardiol* 21: 1285–1291, 1989.
206. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, and Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. *Anticancer Drugs* 22: 128–135, 2011.

207. Pigram WJ, Fuller W, and Hamilton LD. Stereochemistry of intercalation: interaction of daunomycin with DNA. *Nat New Biol* 235: 17–19, 1972.
208. Popelova O, Sterba M, Haskova P, Simunek T, Hroch M, Guncova I, Nachtigal P, Adamcova M, Gersl V, and Mazurova Y. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity *in vivo*: effective rescue of cardiomyocytes from apoptotic cell death. *Br J Cancer* 101: 792–802, 2009.
209. Popelova O, Sterba M, Simunek T, Mazurova Y, Guncova I, Hroch M, Adamcova M, and Gersl V. Deferiprone does not protect against chronic anthracycline cardiotoxicity *in vivo*. *J Pharmacol Exp Ther* 326: 259–269, 2008.
210. Przybyszewski WM, Widel M, and Koterbicka A. Failure of Cardioxane (ICRF-187, dexrazoxane) to limit peroxidative heart damage in rats after gamma irradiation or farmorubicin (4'-epidoxorubicin) treatment. *Toxic Subst Mech* 16: 133–149, 1997.
211. Rajagopalan S, Politi PM, Sinha BK, and Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. *Cancer Res* 48: 4766–4769, 1988.
212. Ramu E, Korach A, Houminer E, Schneider A, Elami A, and Schwab H. Dexrazoxane prevents myocardial ischemia/reperfusion-induced oxidative stress in the rat heart. *Cardiovasc Drugs Ther* 20: 343–348, 2006.
213. Rao VA, Zhang J, Klein SR, Espandiani P, Knapton A, Dickey JS, Herman E, and Shacter EB. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats. *Cancer Chemother Pharmacol* 68: 1125–1134, 2011.
214. Repta AJ, Baltezer MJ, and Bansal PC. Utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane. *J Pharm Sci* 65: 238–242, 1976.
215. Revis NW and Marusic N. Glutathione peroxidase activity and selenium concentration in the hearts of doxorubicin-treated rabbits. *J Mol Cell Cardiol* 10: 945–951, 1978.
216. Rigatos SK, Stathopoulos GP, Dontas I, Perrea-Kotsarelis D, Couris E, Karayannacos PE, and Deliconstantinos G. Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study. *Anticancer Res* 22: 129–134, 2002.
217. Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. *Cardiovasc Toxicol* 7: 135–139, 2007.
218. Robison TW, Giri SN, and Wilson DW. Effects of chronic administration of doxorubicin on myocardial creatine phosphokinase and antioxidant defenses and levels of lipid peroxidation in tissues and plasma of rats. *J Biochem Toxicol* 4: 87–94, 1989.
219. Rosing H, ten Bokkel Huinink WW, van Gijn R, Rombouts RF, Bult A, and Beijnen JH. Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). *Eur J Drug Metab Pharmacokinet* 24: 69–77, 1999.
220. Ruiz-Ruiz C, Robledo G, Cano E, Redondo JM, and Lopez-Rivas A. Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. *J Biol Chem* 278: 31667–31675, 2003.
221. Saad SY, Najjar TA, and Al-Rikabi AC. The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats. *Pharmacol Res* 43: 211–218, 2001.
222. Saad SY, Najjar TA, and Arafah MM. Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats. *Basic Clin Pharmacol Toxicol* 99: 412–417, 2006.
223. Sadzuka Y, Sugiyama T, Shimoi K, Kinai N, and Hirota S. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. *Toxicol Lett* 92: 1–7, 1997.
224. Santos DL, Moreno AJ, Leino RL, Froberg MK, and Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. *Toxicol Appl Pharmacol* 185: 218–227, 2002.
225. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, and Scherrer-Crosbie M. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. *Am J Cardiol* 107: 1375–1380, 2011.
226. Sawyer DB, Fukazawa R, Arstall MA, and Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. *Circ Res* 84: 257–265, 1999.
227. Sayed-Ahmed MM, Salman TM, Gaballah HE, El-Naga SAA, Nicolai R, and Calvani M. Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. *Pharmacol Res* 43: 513–520, 2001.
228. This reference has been deleted.
229. This reference has been deleted.
230. This reference has been deleted.
231. This reference has been deleted.
232. Schroeder PE and Hasinoff BB. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. *Cancer Chemother Pharmacol* 50: 509–513, 2002.
233. Schroeder PE and Hasinoff BB. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat. *Drug Metab Dispos* 33: 1367–1372, 2005.
234. Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, and Hasinoff BB. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. *Cancer Chemother Pharmacol* 52: 167–174, 2003.
235. Schroeder PE, Wang GQ, Burczynski FJ, and Hasinoff BB. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. *Drug Metab Dispos* 33: 719–725, 2005.
- 235a. Scully RE and Lipshultz SE. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. *Cardiovasc Toxicol* 7: 122–128, 2007.
- 235b. Serrano J, Palmeira CM, Kuehl DW, and Wallace KB. Cardiospecific and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. *Biochim Biophys Acta* 1411: 201–205, 1999.
- 235c. Seymour L, Bramwell V, and Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. *Cancer Prev Control* 3: 145–159, 1999.
- 235d. Shapira J, Gotfried M, Lishner M, and Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. *Cancer* 65: 870–873, 1990.
236. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 62: 10–29, 2012.

237. Sieswerda E, Kremer LC, Caron HN, and van Dalen EC. The use of liposomal anthracycline analogues for childhood malignancies: A systematic review. *Eur J Cancer* 47: 2000–2008, 2011.
238. Simunek T, Boer C, Bouwman RA, Vlasblom R, Versteilen AM, Sterba M, Gersl V, Hrdina R, Ponka P, de Lange JJ, Paulus WJ, and Musters RJ. SIH—a novel lipophilic iron chelator—protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. *J Mol Cell Cardiol* 39: 345–354, 2005.
239. Simunek T, Klimtova I, Kaplanova J, Mazurova Y, Adamcova M, Sterba M, Hrdina R, and Gersl V. Rabbit model for *in vivo* study of anthracycline-induced heart failure and for the evaluation of protective agents. *Eur J Heart Fail* 6: 377–387, 2004.
240. Simunek T, Klimtova I, Kaplanova J, Sterba M, Mazurova Y, Adamcova M, Hrdina R, Gersl V, and Ponka P. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. *Pharmacol Res* 51: 223–231, 2005.
241. Simunek T, Sterba M, Holeckova M, Kaplanova J, Klimtova I, Adamcova M, Gersl V, and Hrdina R. Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. *Biometals* 18: 163–169, 2005.
242. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, and Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. *Pharmacol Rep* 61: 154–171, 2009.
243. Simunek T, Sterba M, Popelova O, Kaiserova H, Adamcova M, Hroch M, Haskova P, Ponka P, and Gersl V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. *Br J Pharmacol* 155: 138–148, 2008.
244. Simunek T, Sterba M, Popelova O, Kaiserova H, Potacova A, Adamcova M, Mazurova Y, Ponka P, and Gersl V. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity. *Hemoglobin* 32: 207–215, 2008.
245. Sirker A, Zhang M, and Shah AM. NADPH oxidases in cardiovascular disease: insights from *in vivo* models and clinical studies. *Basic Res Cardiol* 106: 735–747, 2011.
246. Sishi BJ, Bester DJ, Wergeland A, Loos B, Jonassen AK, van Rooyen J, and Engelbrecht AM. Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart. *Exp Biol Med (Maywood)* 237: 219–226, 2012.
247. Sishi BJ, Bester DJ, Wergeland A, Loos B, Jonassen AK, van Rooyen J, and Engelbrecht AM. Daunorubicin therapy is associated with upregulation of E3 ubiquitin ligases in the heart. *Exp Biol Med (Maywood)* 237: 219–226, 2012.
248. Siveski-Iliskovic N, Hill M, Chow DA, and Singal PK. Probulcol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. *Circulation* 91: 10–15, 1995.
249. Siveski-Iliskovic N, Kaul N, and Singal PK. Probulcol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. *Circulation* 89: 2829–2835, 1994.
250. Solem LE, Henry TR, and Wallace KB. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. *Toxicol Appl Pharmacol* 129: 214–222, 1994.
251. Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, Sanger J, and Muggia FM. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. *Am J Med* 78: 555–563, 1985.
252. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. *J Clin Oncol* 10: 117–127, 1992.
253. Steinherz L and Steinherz P. Delayed cardiac toxicity from anthracycline therapy. *Pediatrician* 18: 49–52, 1991.
254. Sterba M, Popelova O, Lenco J, Fucikova A, Brackova E, Mazurova Y, Jirkovsky E, Simunek T, Adamcova M, Mircuda S, Stulik J, and Gersl V. Proteomic insights into chronic anthracycline cardiotoxicity. *J Mol Cell Cardiol* 50: 849–862, 2011.
255. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Guncova I, Kaiserova H, Palicka V, Ponka P, and Gersl V. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH). *Toxicology* 235: 150–166, 2007.
256. Sterba M, Popelova O, Simunek T, Mazurova Y, Potacova A, Adamcova M, Kaiserova H, Ponka P, and Gersl V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. *J Pharmacol Exp Ther* 319: 1336–1347, 2006.
257. Swain SM and Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. *J Cancer Res Clin Oncol* 130: 1–7, 2004.
258. Swain SM, Whaley FS, and Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. *Cancer* 97: 2869–2879, 2003.
259. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchini JR, and Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. *J Clin Oncol* 15: 1333–1340, 1997.
260. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchini JR, and Gams RA. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J Clin Oncol* 15: 1318–1332, 1997.
261. Tan C, Tasaka H, Yu KP, Murphy ML, and Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. *Cancer* 20: 333–353, 1967.
262. Tanabe K, Ikegami Y, Ishida R, and Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. *Cancer Res* 51: 4903–4908, 1991.
263. Tangpong J, Cole MP, Sultana R, Estus S, Vore M, St Clair W, Ratanachaiyavong S, St Clair DK, and Butterfield DA. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. *J Neurochem* 100: 191–201, 2007.
264. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, and Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. *J Clin Oncol* 25: 493–500, 2007.
265. Tesoriere L, Ciaccio M, Valenza M, Bongiorno A, Maresi E, Albiero R, and Livrea MA. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced

- cardiotoxicity and lethality. *J Pharmacol Exp Ther* 269: 430–436, 1994.
266. Thomas C, Vile GF, and Winterbourn CC. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. *Biochem Pharmacol* 45: 1967–1972, 1993.
267. Thomas CE and Aust SD. Release of iron from ferritin by cardiotoxic anthracycline antibiotics. *Arch Biochem Biophys* 248: 684–689, 1986.
268. Thomas X, Le QH, and Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. *Ann Hematol* 81: 504–507, 2002.
269. Tokarska-Schlattner M, Wallimann T, and Schlattner U. Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. *Mol Pharmacol* 61: 516–523, 2002.
270. Tokarska-Schlattner M, Zaugg M, da Silva R, Lucchinetti E, Schaub MC, Wallimann T, and Schlattner U. Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply. *Am J Physiol Heart Circ Physiol* 289: H37–H47, 2005.
271. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, and Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. *J Mol Cell Cardiol* 41: 389–405, 2006.
272. Unverferth DV, Leier CV, Balcerzak SP, and Hamlin RL. Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. *Am J Cardiol* 56: 157–161, 1985.
273. van Acker FA, Boven E, Kramer K, Haenen GR, Bast A, and van der Vijgh WJ. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. *Clin Cancer Res* 7: 1378–1384, 2001.
274. van Acker SA, Kramer K, Grimbergen JA, van den Berg DJ, van der Vijgh WJ, and Bast A. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity. *Br J Pharmacol* 115: 1260–1264, 1995.
275. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. *Cochrane Database Syst Rev* CD003917, 2011.
276. van der Kraaij AM, van Eijk HG, and Koster JF. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. *Circulation* 80: 158–164, 1989.
277. Van Vleet JF, Ferrans VJ, and Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. *Am J Pathol* 99: 13–42, 1980.
278. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA, Jr., and Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. *Biochemistry* 36: 11293–11297, 1997.
279. Vavrova A, Popelova O, Šterba M, Jirkovsky E, Haskova P, Mertlikova-Kaiserova H, Gersl V, and Šimunek T. *In vivo* and *in vitro* assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. *Arch Toxicol* 85: 525–535, 2011.
280. Vecchi A, Spreafico F, Sironi M, Cairo M, and Garattini S. The immunodepressive and hematotoxic activities of N-trifluoro-acetyl-adriamycin-14-valerate. *Eur J Cancer* 16: 1289–1296, 1980.
281. Verhoef V, Bell V, and Filippi J. Effect of the cardioprotective agent Adr-529 (Icrf-187) on the antitumor-activity of doxorubicin. *Proc Am Assoc Cancer Res* 29: 273, 1988.
282. Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, and Bast A. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity. *J Mol Cell Cardiol* 26: 1179–1185, 1994.
283. Von Hoff DD. Phase I trials of dexrazoxane and other potential applications for the agent. *Semin Oncol* 25: 31–36, 1998.
284. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, Rozencweig M, and Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med* 91: 710–717, 1979.
285. Wallace KB. Doxorubicin-induced cardiac mitochondrialopathy. *Pharmacol Toxicol* 93: 105–115, 2003.
286. Wallace KB. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. *Cardiovasc Toxicol* 7: 101–107, 2007.
287. Walter PB, Knutson MD, Paler-Martinez A, Lee S, Xu Y, Viteri FE, and Ames BN. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. *Proc Natl Acad Sci U S A* 99: 2264–2269, 2002.
288. Wang YM, Madanat FF, Kimball JC, Gleiser CA, Ali MK, Kaufman MW, and van Eys J. Effect of vitamin E against adriamycin-induced toxicity in rabbits. *Cancer Res* 40: 1022–1027, 1980.
289. Weinstein DM, Mihm MJ, and Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. *J Pharmacol Exp Ther* 294: 396–401, 2000.
290. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V, Avila N, Jarosinski P, Balis FM, Poplack DG, and Horowitz ME. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. *J Clin Oncol* 14: 362–372, 1996.
291. Whitnall M, Howard J, Ponka P, and Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. *Proc Natl Acad Sci U S A* 103: 14901–14906, 2006.
292. Wilson CO, Beale JM, and Block JH. *Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry*. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2010, x, p. 1010.
293. Wiseman LR and Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. *Drugs* 56: 385–403, 1998.
294. Witteles RM, Fowler MB, and Telli ML. Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented? *Heart Fail Clin* 7: 333–344, 2011.
295. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, Vonhof S, Bickeboller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nurnberg P, Pfreundschuh M, Trumper L, Brockmoller J, and Hasenfuss G. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. *Circulation* 112: 3754–3762, 2005.
296. Wouters KA, Kremer LC, Miller TL, Herman EH, and Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. *Br J Haematol* 131: 561–578, 2005.

297. Wu X and Hasinoff BB. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. *Anticancer Drugs* 16: 93–99, 2005.
298. Xiong Y, Liu X, Lee CP, Chua BH, and Ho YS. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. *Free Radic Biol Med* 41: 46–55, 2006.
299. Xu LJ, Jin L, Pan H, Zhang AZ, Wei G, Li PP, and Lu WY. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. *Acta Pharmacol Sin* 27: 1333–1339, 2006.
300. Xu MF, Ho S, Qian ZM, and Tang PL. Melatonin protects against cardiac toxicity of doxorubicin in rat. *J Pineal Res* 31: 301–307, 2001.
301. Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, Mitsui Y, and Tomoike H. Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. *J Mol Cell Cardiol* 32: 881–889, 2000.
302. Yen HC, Oberley TD, Gairola CG, Szweda LI, and St Clair DK. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. *Arch Biochem Biophys* 362: 59–66, 1999.
303. Yen HC, Oberley TD, Vichitbandha S, Ho YS, and St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. *J Clin Invest* 98: 1253–1260, 1996.
304. Yiakouvaki A, Savovic J, Al-Qenaei A, Dowden J, and Pourzand C. Caged-iron chelators a novel approach towards protecting skin cells against UVA-induced necrotic cell death. *J Invest Dermatol* 126: 2287–2295, 2006.
305. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, and Richardson DR. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. *J Med Chem* 52: 5271–5294, 2009.
306. Zatloukalova L, Filipicky T, Mladenka P, Semecky V, Macakova K, Holeckova M, Vavrova J, Palicka V, and Hrdina R. Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity. *Can J Physiol Pharmacol* 90: 473–484, 2012.
307. Zhang J, Clark JR, Jr., Herman EH, and Ferrans VJ. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. *J Mol Cell Cardiol* 28: 1931–1943, 1996.
308. Zhang J, Herman EH, and Ferrans VJ. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats. *Toxicology* 92: 179–192, 1994.
309. Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ, and Grieve DJ. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. *Cancer Res* 70: 9287–9297, 2010.
310. Zhou L, Sung RY, Li K, Pong NH, Xiang P, Shen J, Ng PC, and Chen Y. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. *Int J Cardiol* 152: 196–201, 2011.
311. Zima T, Tesar V, Crkovska J, Stejskalova A, Platenik J, Teminova J, Nemecek K, Janebova M, and Stipek S. ICRF-187 (dexrazoxan) protects from adriamycin-induced nephrotic syndrome in rats. *Nephrol Dial Transplant* 13: 1975–1979, 1998.
312. Zuppinger C, Timolati F, and Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. *Cardiovasc Toxicol* 7: 61–66, 2007.

Address correspondence to:

Dr. Martin Štěřba

Department of Pharmacology

Faculty of Medicine in Hradec Králové

Charles University in Prague

Šimkova 870

Hradec Králové 500 38

Czech Republic

E-mail: sterbam@lfhk.cuni.cz

Dr. Tomáš Šimůnek

Department of Biochemical Sciences

Faculty of Pharmacy in Hradec Králové

Charles University in Prague

Heyrovského 1203

Hradec Králové 500 05

Czech Republic

E-mail: simunek@faf.cuni.cz

Date of first submission to ARS Central, July 4, 2012; date of acceptance, July 15, 2012.

Abbreviations Used

ANTs = anthracyclines
 CHF = congestive heart failure
 CuZnSOD = cytosolic superoxide dismutase
 DAU = daunorubicin
 DEX = dexrazoxane
 DOX = doxorubicin
 EPI = epirubicin
 LDH = lactate dehydrogenase
 LV = left ventricle
 MnSOD = mitochondrial superoxide dismutase
 mPTP = mitochondrial permeability transition pore
 NOS = nitric oxide synthase
 Nox = NADP oxidases
 PIH = pyridoxal isonicotinoyl hydrazone
 RNS = reactive nitrogen species
 ROS = reactive oxygen species
 SIH = salicylaldehyde isonicotinoyl hydrazone
 smtCK = sarcomeric mitochondrial creatine kinase
 TBARS = thiobarbituric acid-reactive substances
 TOP2 = topoisomerase II